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Abstract 
 
The EURL ECVAM status report provides an update on the progress made in the development, validation and regulatory 
acceptance of alternative methods and approaches since the last report published in April 2013. It is informing on ongoing 
research and development activities, validation studies, peer reviews, recommendations, strategies and international acceptance 
of alternative methods and approaches.    
R&D activities are ongoing for the complex endpoints where the toxicological processes and the mechanistic understanding have 
not been sufficiently elucidated yet and for which 3Rs solutions are more difficult to find. On the other hand, good progress In 
the validation and regulatory acceptance is made in areas where non-animal alternative methods have been developed and 
validated and where the focus lies in an intelligent combination/ integration of the various non-animal approaches. 
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Executive Summary 
The EURL ECVAM status report provides an update on the development, validation and 
regulatory acceptance of alternative methods/approaches since the last report prepared by 
EURL ECVAM in April 2013 in the framework of the Cosmetics Regulation. It covers the year 
2013 to April 2014 and primarily, but not exclusively, EURL ECVAM activities. This year the 
status report also includes updates on alternatives in the areas of vaccines, fish toxicity 
and fish bioconcentration/bioaccumulation, in addition to the health-effect endpoints which 
were traditionally described in previous reports1.  
Research and development activities continued for the complex toxicity areas where robust 
alternative methods and their appropriate integration are still lacking.  These projects have 
led to an improved understanding of toxicological processes and new methodologies and 
tools for mechanistic-based toxicology are emerging. Targeted R&D projects aiming at 
improving fish toxicity testing by reducing or avoiding the use of fish were also supported.  
The Adverse Outcome Pathway (AOP) framework was further developed and taken up by 
the OECD to support the collection, organisation and evaluation of relevant chemical, 
biological and toxicological information for use in human health and environmental risk 
assessment. The framework provides a tool for a knowledge-based safety assessment that 
relies on understanding toxicity and helps to identify where methods should be developed 
and prioritised for validation and how the different approaches should be best integrated 
to ultimately replace the traditional animal tests.  
EURL ECVAM strategies aiming at outlining holistic solutions to achieve reduction, 
refinement and replacement of animal testing while maintaining or improving human and 
environmental protection were developed in the areas of genotoxicity, acute systemic 
toxicity, aquatic toxicicity and bioconcentration/bioaccumulation testing and toxicokinetics. 
Test submissions addressing predominantly the endpoints of topical toxicity (skin and eye 
irritation) and skin sensitisation were received, followed by methods for endocrine 
disruption, genotoxicity, acute fish toxicity and intestinal permeability testing. In order to 
explore the availability and the development status of in vitro methods in the priority area 
of toxicokinetics and in view to solicit their submission, EURL ECVAM launched a survey and 
a call for in vitro methods for estimating human hepatic metabolic clearance/stability.   
The EURL ECVAM coordinated validation studies on eye irritation (EpiOcular EIT), and CYP-
induction were completed in 2013 and in 2014 they entered peer review by the ECVAM 
Scientific Advisory Committee (ESAC). The ESAC peer review of the h-CLAT method (skin 
sensitisation) was finalised in 2014. Validation studies on Estrogen Receptor and Androgen 
Receptor Transactivation Assays (ERTA/ARTA) are either still on-going (ERTA) or were 
recently started (ARTA). The first validation study making use of the recently established 
                                              
1
 http://ec.europa.eu/consumers/sectors/cosmetics/animal-testing/index_en.htm 
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European Union Network of Laboratories for the Validation of Alternative Methods (EU-
NETVAL) was launched in 2014 for the validation of an ARTA. 
Several validation studies on alternative methods for potency and safety testing of various 
vaccines for human and veterinary use are currently ongoing or planned to start in 2014 
within the framework of the Biological Standardisation Programme (BSP) of the European 
Directorate for the Quality of Medicines & HealthCare (EDQM; Council of Europe) and co-
sponsored by the European Commission. 
External validation studies (i.e. not co-ordinated by EURL ECVAM) in the areas of 
genotoxicity, carcinogenicity, endocrine disruption, eye and skin irritation were submitted to 
EURL ECVAM in view of ESAC peer review.   The external validation study on the Bhas 42 
CTA was peer reviewed by ESAC and a EURL ECVAM Recommendation was published in 
2013. The ESAC peer review of a test method based on a reconstructed human epidermis 
for skin irritation testing, also externally validated, is currently on-going. 
The recently established EURL ECVAM Recommendations are becoming an effective tool to 
promote and facilitate international regulatory acceptance of validated methods. These 
Recommendations provide EURL ECVAM views on the validity of a test method including its 
limitations and proper scientific use, possible regulatory applicability, and possible follow-
up activities in view of addressing knowledge gaps. They are developed in close 
consultation with EURL ECVAM's advisory network of regulators (Preliminary Assessment of 
Regulatory Relevance (PARERE) network), its stakeholder forum (ESTAF) and international 
collaboration partners (ICATM).  
EURL ECVAM Recommendations on the validated 3T3 Neutral Red Uptake (3T3 NRU) 
cytotoxicity assay, the Direct Peptide Reactivity assay (DPRA), the KeratinoSens and on the 
Bhas42 cell transformation assay were published in 2013/2014. The Recommendation on 
the Zebrafish embryotoxicity test is currently undergoing public commenting. Draft Test 
Guidelines (TG) on all the validated and peer reviewed methods have been prepared and 
submitted to the OECD Test Guidelines Programme, apart from the 3T3 NRU cytotoxicity 
test which is already an OECD Guidance document. A TG based on the Fish embryo acute 
toxicity (FET) test was already published as OECD TG 236 in 2013. 
Further developments were made to content and functionality of web-based 
communication and dissemination tools on alternative methods hosted by EURL ECVAM, 
including the database on alternative methods, DB-ALM, and the system for tracking 
progress of alternative methods through validation and regulatory acceptance (TSAR). A 
revised version of the EURL ECVAM Search Guide was also published.  
The scope of collaboration with partners within the International Cooperation on Alternative 
Testing Methods (ICATM) working on the validation and acceptance of alternative methods 
was extended to include increased alignment of respective workflows, earlier consultation 
and joint evaluation of promising methods, and coordination of post-validation activities to 
facilitate regulatory acceptance and uptake globally.   
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1. Introduction 
The EURL ECVAM status report has been prepared with a view to respond to the frequent 
requests of stakeholders on the status of alternative methods and approaches. It is 
intended to inform many interested parties and serve multiple purposes, including 
providing input to the annual Commission report prepared by DG SANCO on the progress 
made in the development, validation and regulatory acceptance of alternative 
methods/approaches required by Regulation 1223/2009 on cosmetic products. The status 
report describes primarily, but not exclusively, activities that EURL ECVAM has undertaken 
or has been involved in during the period from March 2013 to April 2014. The previous 
EURL ECVAM progress report was published in May 2013 and covered the years 2010 to 
April 20132. 
Unlike previous reports that primarily focused on the regulatory toxicity endpoints of 
relevance to the Cosmetics Regulation, this report also includes updates on the areas of 
vaccines, fish toxicity and fish bioconcentration/bioaccumulation.  Moreover, the layout of 
the report has been adapted to follow more the lifecycle of alternative toxicity tests and 
approaches destined for regulatory use, i.e. from research and development activities, 
through validation, to regulatory uptake.  
Testing of vaccines and 3Rs methods 
Vaccines play an important role in the prevention of human and animal diseases. They are 
heterogenous biological products containing components as antigens, adjuvants, excipients, 
and preservatives. Their composition and manufacturing process varies depending on the 
type of vaccine and potential use. All vaccines (as other medicinal products) for human or 
veterinary use have to be authorised and registered either at Member State or Community, 
i.e. European Medicines Agency, level before they can be placed on the EU market 
(Directive 2001/82/EC; EC, 2001a; Directive 2001/83/EC; EC, 2001b and amendments). 
Requirements which have to be met by a given vaccine are laid down in e.g. European 
Pharmacopoeia monographs, EU guidelines or WHO recommendations. In addition to the 
tests carried out for obtaining the marketing authorisation, the quality of a vaccine batch 
must be controlled by the manufacturer and, in Europe, by an Official Medicinal Control 
Laboratory (OMCL) before it is released for use. 
Traditionally, laboratory animals have played a major role in batch release testing of 
vaccines and still many are required, in particular for potency testing of inactivated 
vaccines (e.g. tetanus, diphtheria, pertussis, rabies, clostridial, leptospiral vaccines) and 
safety testing of e.g. acellular pertussis vaccine, tetanus vaccine, and oral polio vaccines.  
Over the last two decades, numerous alternative methods to classical animal tests have 
been developed, validated, incorporated into European Pharmacopoeia monographs 
(Council of Europe, 2013) and successfully implemented at manufacturer and OMCL level.  
                                              
2
 see http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/eurl-ecvam-releases-2013-progress-report-development-
validation-regulatory-acceptance-alternative-methods. 
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Moreover, the concept of vaccine quality control is changing as emphasis is being put on 
ensuring the consistency of production of a vaccine (Hendriksen et al, 2008; De Mattia et 
al, 2012). This shift of focus from the final product (batch) to the production process by 
using intensive in-process testing and modern quality systems (consistency approach) is 
already in place for new generation vaccines, which are better defined and allow the use of 
in vitro and physico-chemical methods for their characterisation and quality control. The 
challenge will be to implement the consistency approach for established vaccines e.g. 
DTaP, rabies, clostridial vaccines, which are less defined and therefore more difficult to 
characterise (see paragraph 5.5.2.2, EPAA vaccine project).   
Fish Toxicity and Fish Bioconcentration/Bioaccumulation 
Environmental hazard identification is an important component of the safety assessment 
of all types of chemicals (e.g. industrial chemicals, plant protection products, biocides, 
pharmaceuticals, feed additives) relevant in the context of EU and international regulations 
aiming at the protection of the environment. Vertebrate animals used for environmental 
hazard and risk assessment are fish, amphibia, birds and, on rare occasions, mammals. A 
recent paper of Scholz et al (2013) summarises possibilities to reduce the use of 
vertebrates in environmental risk assessment covering aquatic toxicity, avian toxicity, 
bioaccumulation and endocrine activity.  
Over the past ten years, EURL ECVAM's activities have been focused on 3Rs methods for 
aquatic (fish) toxicity testing and fish bioconcentration/bioaccumulation testing. Work 
carried out at the JRC resulted in the threshold approach for acute fish toxicity testing 
(OECD guidance document 126; OECD, 2010), a testing strategy which has the potential to 
significantly reduce the number of animals used for acute fish toxicity testing. The 
threshold approach is included in the ITS proposed in the REACH guidance document on 
aquatic toxicity (ECHA, 2012), in the biocides regulation (EU, 2012) and plant protection 
products data requirements (EU, 2013a; EU, 2013b). More recently, EURL ECVAM 
coordinated on behalf of OECD the validation of the zebrafish embryo acute toxicity test 
which resulted in the OECD TG 236 Fish embryo acute toxicity (FET) test (OECD, 2013; see 
also XX) EURL ECVAM recommendation).   
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2. Research and Development Activities Related to Alternative 
Methods 
2.1 SEURAT-1 
2.1.1 Overview of SEURAT-1 
With the collective aim of ultimately replacing in vivo repeated dose systemic toxicity 
testing with animal-free solutions, the SEURAT-1 cluster is the largest EU initiative ever 
undertaken on alternative methods to animal testing, comprising 70 European research 
partners equally co-financed through a unique public-private partnership between the 
European Commission (FP7 Programme administered by DG Research & Innovation) and 
Cosmetics Europe. SEURAT-1 combines five research projects (COSMOS, Scr&Tox, 
DETECTIVE, HeMiBio and NOTOX), a central data and knowledge management project 
(ToxBank) and a coordination action (COACH). The Systems Toxicology Unit/EURL ECVAM 
(JRC-IHCP), is heavily involved in three of the five complementary research projects, and 
manages the coordination efforts of the entire cluster.  
 
Figure 1. Research Projects of SEURAT-1 
SEURAT-1 started its activities in 2011 and all the projects are by now well advanced in 
their work programmes and a wide variety of new methodologies and tools for 
mechanistic-based toxicology are emerging, such as complex bioreactors for engineering 
human tissues, innovative 'omics' techniques, differentiation protocols for human induced 
pluripotent stem cells and modelling tools.  
At the centre of all activities there is much emphasis on Proof-of-Concept (PoCs) case 
studies that will demonstrate the implementation of the SEURAT-1 research strategy, i.e. to 
develop complementary theoretical, computational and experimental (in vitro) models to 
predict toxicity in humans and apply the predictions in safety assessment of chemicals (see 
below).  
2.1.2 Seurat-1 related collaboration between JRC and Cosmetics Europe  
A collaborative arrangement between the JRC and Cosmetics Europe aims to supplement 
the work programme of the SEURAT-1 cluster. This research initiative, although motivated 
by the Cosmetic industry, is also relevant to other industrial sectors (e.g. industrial 
chemicals, pharmaceuticals).  
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The aims of this project are (a) to facilitate cluster interaction and to demonstrate proof-
of-concept at three different levels, namely 1) defining mode-of-action (MoA), 2) predicting 
toxicity, and 3) supporting safety assessment decisions, (b) to supplement the 
computational modelling activities of the cluster and (c) to generate large reference 
datasets to support the establishment of toxicological MoA. In brief, the following work was 
carried out by EURL ECVAM: 
 An assessment framework was proposed that could be used to predict the potential 
toxicity of a substance, under repeat dose exposure conditions, by using a range of 
complementary non-animal methods that are integrated according a toxicological 
MoA framework. This was followed by the cluster-wide definition of predictive 
toxicology case studies involving collaboration across the six projects within the 
SEURAT-1 cluster; 
 An open source software tool was developed for simulating the long-term (repeat 
dose) toxic effects of chemicals, including substances in cosmetics and personal 
care products, in in vitro systems. The approach was based on the previously 
developed Virtual Cell Based Assay (VCBA) (Zaldivar et al, 2010, 2011, 2012), re-
coded and re-implemented in the open-source KNIME (– The Konstanz Information 
Miner)  platform. Two case study compounds, paracetamol (acetaminophen) and 
amiodarone were selected to illustrate the usefulness of this tool in simulating the 
repeat dose toxicity of compounds; 
 An open source approach was developed for predicting the potential of chemicals, 
which can also be used for substances in cosmetics and personal care products 
(ingredients and impurities), to bioaccumulate in humans following realistic 
exposure scenarios. The approach is based on a PBTK model implemented as a 
KNIME workflow, an open-source application which is freely available on request; 
 An illustration of how in silico models describing the kinetics and dynamics of 
chemicals in cell cultures and the human body can be applied in risk assessment to 
translate in vitro toxicity data into predictions of human toxicity under defined 
consumer exposure scenarios (in vitro to in vivo extrapolation; IVIVE). The consumer 
exposure scenarios selected were based on the expected use of three caffeine-
containing cosmetic products; 
 Review of the availability of in silico and in vitro methods for assessing dermal 
bioavailability as being dependent on dermal penetration and first pass dermal 
metabolism. In the safety assessment of cosmetics, the measurement or simulation 
of these processes is needed to apply methodology for extrapolating from oral-to-
dermal exposure scenarios, and in particular for extrapolating from repeat dose oral 
toxicity data to repeat dose effects in the skin; 
 Approach to design and optimise treatment protocols for repeat dose in vitro 
experiments, based on computational modelling, analytical chemistry tools and 
mechanistic knowledge.  A step-by-step guidance on how to perform repeat dose in 
vitro experiments, consisting of the seven steps, was provided to illustrate the 
approach;  
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 Concentration-response data on 100 reference chemicals relevant to hepatotoxicity 
MoA were provided together with a summary of the scientific/technical work 
performed to obtain the dataset. The human metabolically competent cell line 
HepaRG was used for testing reactive oxygen species formation as indicator of 
oxidative stress and the formation of neutral lipid droplets as indicator of chemical-
induced steatosis. Nuclear intensity (an indicator for DNA condensation), nuclear 
area (an indicator for cell injury) and cell count (an indicator for cell viability) were 
also analysed and this multi-parametric analysis allowed a categorisation of the 
tested chemicals. The full raw dataset as well as the protocols used are available 
for the entire SEURAT-1 cluster for further data analysis through the ToxBank 
database. 
2.1.3 COSMOS project  
The COSMOS project (http://www.cosmostox.eu/) is developing publicly available 
computational workflows based on the integrated use of open-access and open-source 
models for the prediction of repeated dose toxicity (Anzali et al, 2012). This includes: a) the 
establishment of an inventory of cosmetic substances (including identifiers and chemical 
structures) and a repeat dose toxicity database (including oral and dermal data); b) the 
development of novel ways of establishing thresholds of toxicological concern (TTC), based 
on innovative chemistry based prediction approaches and biokinetic modelling. 
2.1.4 COSMOS database 
Although several databases for chronic toxicity data are available, no single repository of 
chronic toxicity data exists that is open and transparent and includes all aspects of the 
data such as protocol details. Therefore, the COSMOS project is building a new freely 
accessible database as a comprehensive and reliable resource for repeated dose toxicity 
data. The COSMOS database (Rathman et al, 2013) is also linked to high quality and 
validated chemical structures to facilitate modelling. The first version of the database 
(v1.0) was released in December 2013 and is accessible via the COSMOS project website. 
V1.0 of the database contains oral repeat-dose toxicity data (subacute, subchronic, and 
chronic studies as well as carcinogenicity studies) for over 1000 cosmetics-related 
chemicals. 
2.1.5 PB(T)K modelling 
Physiologically-based kinetic (PB(T)K) models can be used to predict in vivo toxicokinetics 
(e.g. time-course of blood or tissue concentrations of a chemical) based on in vitro 
measurements of the underlying processes of absorption, distribution, metabolism and 
excretion (in vitro to in vivo extrapolation; IVIVE), as well as to extrapolate existing animal 
blood time-courses of a chemical for one exposure route to another exposure route (route-
to-route extrapolation; RtR), e.g. oral-to-dermal extrapolation. During 2013-2014, these 
PB(T)K modelling approaches have been applied for selected compounds within COSMOS 
(Pery et al, 2013, Gajewska et al, 2014). In addition, a survey with respect to in vitro 
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hepatic metabolic clearance/stability methods has been published on the JRC website. The 
results of these methods should directly feed into the PB(T)K models. A workshop on this 
issue will be organised in May 2014.  
2.2 Adverse Outcome Pathways (AOPs) 
Improved understanding of toxicological processes, together with advances in 
toxicogenomics, bioinformatics, systems biology and computational toxicology, facilitate 
the paradigm shift in the approach to regulatory toxicity testing and risk assessment. In 
this context, the Adverse Outcome Pathway (AOP) framework has been developed to 
support the collection, organisation and evaluation of relevant chemical, biological and 
toxicological information for use in human health risk assessment. It provides a tool for a 
knowledge-based safety assessment that relies on understanding toxicity, rather than 
simply observing its effects.  
 
The AOP construct is based on the mechanistic understanding of toxicological processes on 
different biological levels that ultimately lead to an adverse health effect, defined as a 
series of key events, starting from an initial interaction of a chemical with a biological 
target (molecular initiating event, MIE) and consecutively showing the key events (KEs) at 
the molecular, cellular, tissue, organ, and organism levels.  
 
The emphasis moves away from demonstrating the final adversity, to demonstrating the 
initiating and intermediate events. Among other things, this approach allows the profiling 
of chemicals according to their potential to trigger such events, instead of the traditional 
way of associating them with an apical adverse endpoint. 
 
The AOPs elaborated to date are mainly qualitative pathway descriptions, and further 
research is necessary to develop a more-precise characterisation of the dynamic 
relationships between actors and events also in quantitative terms.  Even though the level 
of information currently available is not sufficient to perform a comprehensive risk 
assessment, a well-described AOP may still provide useful information for many purposes, 
such as priority setting for further testing, hazard identification, classification and labelling, 
and the development of an integrated test system or read-across for categorisation of 
chemicals. All this will help to refine, reduce and/or replace conventional in vivo animal 
testing. 
 
To coordinate and harmonise various international efforts in AOP development, the OECD 
launched the AOP Development Programme in January 2013. This programme is managed 
by the Extended Advisory Group on Molecular Screening and Toxicogenomics that the EURL 
ECVAM is co-chairing together with the US Environmental Protection Agency (EPA). 
 
In this context an AOP Knowledge Base (AOP KB) is being developed in a collaborative 
effort between EURL ECVAM and US EPA to facilitate the collection, integration, curation 
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and dissemination of current mechanistic pathway knowledge contributed and evaluated 
by a wide range of experts.  The OECD has launched the AOP-KB project in order to give 
the global scientific and regulatory communities the possibility to enter, share and discuss 
their AOP related knowledge within one comprehensive platform. Thanks to this IT system, 
AOP developers can create an AOP wiki page and then build an AOP by linking related 
information about Molecular Initiating Events, intermediate Key Events, Adverse Outcomes 
and Chemical Initiators. Controlled-vocabulary drop-down lists from which to select 
Methods, Actions, Biological Targets, Life stages, Species etc. related to the AOP simplify 
the entry of ontology-based information. Information regarding Key Events and Adverse 
Outcomes shared among multiple AOPs is stored on a single page to eliminate redundant 
entries and make the collective knowledge about those entities available in all AOPs 
containing them. This format also facilitates the identification of potential intersections 
and cross-talk among AOPs. 
Phase 1 of the AOP-KB project, the AOP Wiki, is now finished, and some twenty AOPs have 
been entered into the system, where they are now reviewed, discussed and enhanced - 
with a view to an eventual adoption at OECD level. The next phase of the project will add 
quantitative and graphical elements. 
 
An example of an AOP-based research strategy and of how new insights into mechanistic 
toxicology can be applied for safety assessment, is given by SEURAT-1 in relation to 
repeat-dose systemic toxicity (see paragraph 2.1 above). In this context, EURL ECVAM took 
the lead on the development of two AOPs related to liver fibrosis and liver steatosis, 
following the OECD guidance and template. These are complementing the on-going 
experiments at EURL ECVAM for evaluating responses to toxicants by combining a relevant 
human liver cell model (HepaRG cells) with high-content cellular imaging, implemented on 
an automated platform for high-throughput screening,. 
 
Liver fibrosis is a reversible wound healing response to a variety of chronic injuries 
including toxic injury from chemicals. It results from an imbalance between the deposition 
and degradation of extracellular matrix (ECM) and a change of ECM composition. 
Pathogenic fibrosis typically results from chronic injury with sustained production of 
growth factors and fibrogenic cytokines in which inflammation, tissue destruction, and 
repair processes occur simultaneously. The case study with the qualitative description of 
the AOP from Protein Alkylation to Liver Fibrosis using Allyl Alcohol and Carbon 
Tetrachloride as reference chemicals reports a plausible but incomplete pathway 
description and needs further refinement and in-depth analysis with added information on 
gene expression, quantitative data on dose-response relationships and temporal 
sequences.  
 
A project to expand this case study to a more widely applicable AOP by looking for data on 
quantitative and temporal relationships and exploring the chemical space that leads to 
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fibrosis has been accepted as an OECD AOP development project and included in the work 
plan of the AOP Development Programme. 
 
The use of nanoparticles in foods and food products and therefore exposure via ingestions 
is rapidly growing. Nanotoxicology is a complex field with currently many knowledge gaps 
and a better understanding of the mechanisms of toxicity of nanoparticles is needed.  
EURL ECVAM is also working on the development of AOPs specific to nanoparticle-induced 
liver toxicity.   
 
To date there are only few descriptions of AOPs leading to neurotoxicity.  This lack of AOPs, 
and in particular the lack of MIEs, has made it difficult to evaluate the predictive ability of 
high-throughput chemical testing for neurotoxicity. As a first step in applying the AOP 
framework to adverse health outcomes associated with exposure to exogenous neurotoxic 
substances, EURL ECVAM organized a workshop in March 2013 to identify potential AOPs 
relevant to neurotoxic and developmental neurotoxic outcomes.  Although the AOPs 
outlined during the workshop are not complete, they serve as a basis for further research 
and identification of MIEs and Key Events (KEs). Following this workshop EURL ECVAM is 
focussing on the development of an AOP to developmental neurotoxicity via thyroid 
disruption. 
 
Another project within EURL ECVAM is the AOP development for Peroxisome Proliferator-
Activated Receptors (PPAR)-mediated rodent reproductive toxicity. There is substantial 
evidence for the involvement of PPAR in toxicity to male and female reproductive function. 
However the underlying mechanisms of these effects still require further investigations.   
 
A further activity is the identification of common mechanisms, like mitochondrial toxicity or 
cytoskeleton destabilisation, which are associated with different toxicological endpoints. 
2.3 Fish Toxicity R&D projects 
Three R&D projects related to fish toxicity, which are of specific interest to EURL ECVAM, 
are described here below. 
2.3.1 EPAA scientific award project 2012 – Increasing the predictive capacity of 
the fish embryo test3  
EURL ECVAM is on the scientific board of this research project awarded to Nils Kluever 
(UFZ, Leipzig, Germany). The overall aim of the project is to improve the Zebrafish embryo 
acute toxicity test (OECD TG236, OECD, 2013a) for predicting fish acute toxicity. For this 
purpose, UFZ analysed acute fish toxicity data (LC50) derived with juvenile/adult fish 
(OECD TG 203; OECD, 1992) and fish embryos. In case that fish LC50 values indicate a 
significantly higher toxicity than fish embryo LC50 values for a given chemical, possible 
                                              
3
 http://ec.europa.eu/enterprise/epaa/platform-science/award/science_award_en.htm 
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reasons for this difference will be investigated, e.g. chemical properties, protocol used for 
the fish embryo test (age of the embryos, exposure duration, etc.), and metabolism. If 
deemed necessary, chemicals were tested in the Zebrafish embryo acute toxicity test and, 
in addition to the four lethal endpoint, sublethal endpoints were used to determine toxic 
effects. Preliminary results indicate that the predictivity of the Zebrafish embryo acute 
toxicity test for chemicals with neurotoxic mode of action being highly toxic to juvenile and 
adult fish may be improved by assessing sublethal endpoints. The project was finalised in 
2013 and publication of the results is in preparation. It is further foreseen to include the 
findings into the planned OECD guidance document on the use of the Zebrafish embryo 
acute toxicity test for acute fish toxicity testing.  
2.3.2 Use of a fish cell line-based cytotoxicity assay for acute fish toxicity testing 
Within the CEllSens project4, the RTgill-W1 (rainbow trout gill cell line) cytotoxicity assay 
was standardised and based on the promising results for the 35 organic chemicals tested, 
Tanneberger et al (2013) propose its use for acute fish toxicity testing. However, further 
evaluation of its reproducibility, predictive capacity and applicability domain is needed. As a 
follow-up of the CEllSens project, EAWAG (K. Schirmer) launched a ring trial assessing the 
transferability of the assay. In addition, the method was submitted to EURL ECVAM in early 
2014 and the assessment of the test submission is ongoing (see paragraph 3.8).  
2.3.3 Development of AOPs for chronic fish toxicity testing  
Several research groups are working on the identification and description of potential AOPs 
relevant to chronic fish toxicity, which is currently assessed with fish early life-stage (FELS) 
test (OECD TG 210; OECD 2013b). In 2013, the CEFIC LRI-funded project (LRI-ECO20-UA) 
Development of an alternative testing strategy for the fish early life-stage test for 
predicting chronic toxicity started. It aims to map FELS-relevant AOPs, develop an in vitro 
toolbox for screening FELS-relevant AOPs (Tier 1) and Zebrafish embryo based assays (Tier 
2). The report of a recent ILSI HESI workshop (Villeneuve et al., 2014) discusses AOPs 
relevant to FELS toxicity and how they could be discovered and annotated. The authors 
define key events in the development of a fish embryo as development of the central 
nervous system, cardiovascular system, liver, kidney, etc. They give examples of 
hypothesised AOPs focusing on impaired swim bladder inflation and reduced survival of 
young fish. 
  
                                              
4
 ECO8; http://www.cefic-lri.org/projects 
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3. Test Method Submissions 
3.1 Introduction to Test Method Submissions 
New in vitro methods usually enter the EURL ECVAM validation workflow through a two-
step test submission  process that target very broadly all human health(-related) and 
environmental effects and biologicals. A tracking system of alternative methods towards 
regulatory acceptance provides an overview of all test methods that were submitted to 
EURL ECVAM for validation and/or peer review from 2008 up to now5. This tracking system 
is currently under revision to add information on the validation and regulatory acceptance 
process of submitted test methods. 
Ideally, test submissions are assessed in the context of EURL ECVAM strategy papers that 
were, or are being defined in various toxicological areas such as e.g.  skin sensitisation, 
genotoxicity, acute systemic toxicity, fish toxicity, (developmental) neurotoxicity and 
toxicokinetics (TK, see paragraph 8.5).  
The toxicokinetic strategy paper for example, identified hepatic metabolic clearance as a 
fundamental piece of necessary information since it plays a key role in the transformation 
and the elimination of chemicals from the human body. As various in vitro methods for 
human hepatic metabolic clearance/stability have been developed in recent times and in 
order to solicit the submission of the most promising ones, EURL ECVAM has recently 
launched a survey and a call for in vitro methods for estimating human hepatic metabolic 
clearance/stability6.   
In future, beside the normal test submission process mentioned above, EURL ECVAM may 
launch other similar calls for in vitro methods in areas that have been identified as 
regulatory priority areas and where in vitro methods may have been sufficiently developed 
and optimised to enter the EURL ECVAM validation workflow. 
During the time period covered by this report, in total, 9 test methods have been submitted 
to EURL ECVAM, of which 4 were pre-submissions, reporting information in the Test Pre-
Submission Form (TPF), and 5 were full submissions, reporting information in the Test 
Submission Template (TST), normally complemented by several annexes. Noteworthy, out 
of the 5 full submissions, 4 were on external validation studies submitted to EURL ECVAM 
in view of ESAC peer review. Beside the assessment of the test submissions received from 
2013 to April 2014, assessments of test submissions received in late 2012 were also 
conducted and are reported here below. The majority of test submissions received by EURL 
ECVAM in the time period covered by this report address the skin sensitisation endpoint 
followed by similar test methods (so-called "me-too's") for skin irritation testing.  One 
method was submitted in the area of eye irritation, genotoxicity, acute fish toxicity 
intestinal permeability and endocrine disruption, respectively. 
                                              
5
 see http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/test-submission 
6
 see http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/eu-netval/in-vitro-methods-survey-March-2014 
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3.2 Test method submissions related to skin sensitisation  
The Genomic Allergen Rapid Detection (GARD) test method is a transcriptomics-based in 
vitro assay proposed to discriminate between skin sensitising and non-sensitising 
chemicals on the basis of the expression level of mRNA transcripts for a panel of 200 
genes analysed using a whole genome array (Johansson et al., 2013). The cell line used is 
the human myeloid leukemia-derived cell line MUTZ-3, as a model for in vivo dendritic cells 
(DC) (Johansson et al., 2011, 2013). Optimisation work is ongoing to further optimise the 
prediction model for potency prediction and to transfer the assay to a real-time 
quantitative polymerase chain reaction (qRT-PCR) platform. EURL ECVAM is monitoring 
these developments and the test developer has been invited to resubmit the test method 
once this work has been finalised. 
The RHE IL18 Potency Test represents an update of the two-tiered approach, previously 
submitted to EURL-ECVAM. In the RHE IL18 Potency Test the two readouts, intracellular IL-
18 released used to discriminate between sensitisers and non-sensitisers, and viability as a 
measure of sensitising potency are combined in a single test which uses reconstructed 
human epidermis (RhE) as test system (Gibbs et al., 2013). The test method is proposed as 
an improvement to the two-tiered approach since it more closely resembles the 
architecture and the barrier function of the normal human epidermis and allows testing 
low water soluble chemicals since the protocol foresees the use of solvents and solvent 
mixtures with different polarities.  
The updated Myeloid U937 Skin Sensitisation Test (MUSST), which distinguishes sensitisers 
from non-sensitisers on the basis of CD86 membrane protein enhanced expression in 
U937 cells, includes an addition to the prediction model, consisting of a score derived from 
6 rules that allows classifying a chemical, which would have been considered inconclusive 
on the basis of the original prediction model, as a sensitiser or non-sensitiser. The MUSST 
prediction model and its addition have been incorporated in an application called “MUSST 
PREDICTOR” which allows automated data analysis and derivation of individual run 
conclusions and the final chemical's classification.  The chemical solubilisation procedure 
was also revised to minimise variability in vehicle selection. 
The SENS-IS is a gene expression-based test method proposed to discriminate between 
sensitisers, non-sensitisers and irritants by analysing the expression of a panel of 65  
genes grouped in one gene set for irritancy and two (SENS-IS and ARE) for sensitisation. A 
test substance is classified as sensitizer on the basis of the number of overexpressed 
genes (compared to the solvent control) measured by qRT-PCR in Episkin tissues (SkinEthic, 
France). In addition, the test method allows the classification of sensitisers into potency 
categories on the basis of the concentration of chemical needed to induce a positive 
response. 
The RHE IL 18 Potency Test, the updated MUSST and the SENS-IS are being evaluated in 
external multi-laboratories studies (i.e. not coordinated by EURL ECVAM). In case the 
validation of these test methods will be successfully finalised, the information generated 
will be submitted to EURL ECVAM for evaluation and eventual ESAC peer review. 
19 
 
The Skin Sensitizer Predictor is a test method proposed for skin sensitisation hazard 
assessment. The expression levels of mRNA transcripts for a set of four genes and proteins 
involved in three different intracellular signalling pathways are quantified following 
treatment of a mouse foetal skin-derived DC cell line (FSDC) with test chemicals. Readouts 
are then used in a prediction model based on linear discriminant analysis to derive a 
Prediction Score for distinguishing between sensitising and non-sensitising chemicals 
(Neves et al., 2013). Following the evaluation of the submitted information EURL ECVAM 
decided not to pursue this submission further since it was felt that additional optimization 
work on the test method was needed. 
3.3 Test method submission related to intestinal permeability  
The Caco-2 permeability assay was received in 2013. It is an in vitro assay that measures 
the permeability of compounds through a human intestinal epithelial cell barrier. The 
intestinal permeability measured is expressed as apparent permeability (Papp value). The 
test method was proposed for bioequivalence testing of pharmaceuticals, while its 
relevance to chemicals testing was uncertain. Some shortcomings were identified during 
the evaluation process. For instance, there was no clear evidence on the improvements 
offered by the Caco-2 permeability assay proposed in comparison to other available 
assays. It was also unclear how the apparent permeability's cut off values proposed for 
classification were derived. The test method was not prioritised since its potential 3Rs 
impact was unclear. 
3.4 Test method submission related to genotoxicity  
A full test submission was received in 2013 on a method intended to predict the in vivo 
genotoxic potential of chemicals: the Green Screen HCTM (GSHC) assay. The GSHC is a 
microplate format genotoxicity plus cytotoxicity screening assay which uses the DNA 
damage-inducible "Growth Arrest and DNA Damage 45 alpha" (GADD45a) - Green 
Fluorescent Protein (GFP) reporter gene, expressed in the p53-competent human 
lymphoblastoid TK6 cell line (Hastwell et al., 2006; Jagger et al., 2009). Upon DNA 
damaging agent treatment, GADD45a is highly induced mostly in a p53-dependent 
manner. When GADD45a transcription is increased over its constitutive level, cells 
accumulate GFP, the fluorescence of which can be measured as a proportional assessment 
of genome damage and genotoxic stress. 
Based on the information provided, the method appears to be mechanistically and 
biologically relevant in relation to genotoxicity. A well standardised protocol is already 
published in the EURL ECVAM DB-ALM (http://ecvam-dbalm.jrc.ec.europa.eu/).  The data 
provided in this submission are convincing enough to support the use of the test method as 
a screening tool in early phases of compound discovery and development. However, due to 
the properties of the method as a general indicator of genotoxicity that does not allow the 
identification of the specific mode of genotoxic action, the actual role of the GreenScreen 
HCTM method within current regulatory testing approaches needs to be further elucidated.  
In the light of this, and before considering peer review by the ECVAM Scientific Advisory 
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Committee (ESAC), the EURL ECVAM network of regulators (PARERE - Preliminary 
Assessment of Regulatory Relevance) will be consulted to further the assessment of 
regulatory relevance of the test method.  
3.5 Test method submissions related to skin irritation  
EURL ECVAM regularly receive requests and inquiries on technical matters relating to the 
development, optimisation and validation of in vitro skin irritation test methods based on 
tissue engineered Reconstructed human Epidermis (RhE) models. Moreover, all formal test 
submissions received in the period covered by this report concern RhE-based test methods 
seeking formal evaluation and validation by EURL ECVAM in reference to the Performance 
Standards for in vitro skin irritation testing (EURL ECVAM 2009; OECD TG 439, 2010). The 
submissions concern requests for the evaluation of similarity of test methods prior to the 
execution of external PS-based validation studies. In response to such submissions, EURL 
ECVAM conducts an assessment of the compliance of the submitted test methods with the 
criteria as outlined in the 'essential test method components' of the PS. These assessments 
may be subject to scientific judgements since the PS do not provide a simple "tick-box 
approach" and are thus reviewed and, if appropriate, confirmed by ESAC. Other submissions 
concern finalised PS-based validation studies conducted by industry and submitted for 
evaluation by EURL ECVAM and eventual ESAC peer review.  
Importantly, so far all internationally accepted test methods for skin irritation testing 
(apart from the traditional animal test) are in vitro test methods based on the 
Reconstructed Human Epidermis (RhE) and the majority of these test methods have been 
validated on the basis of the EURL ECVAM PS for in vitro skin irritation testing). As outlined 
above, all test methods submitted to EURL ECVAM are based on this technology, with 
minor variations relating to specifications of the test system or the way the test system 
(i.e. RhE) is being produced.  
The epiCS® test method concerns an external validation study based on the Performance 
Standards for in vitro skin irritation testing (EURL ECVAM, 2009; OECD TG439). As for other 
RhE-based methods, the same test system (i.e. RhE skin model) is used both for skin 
irritation and skin corrosion testing: depending on the health effect to be assessed the 
appropriate SOP (either for corrosion or for irritation assessment) needs to be chosen. The 
test system formerly marketed as "EST-1000" has been recently renamed to epiCS®. The 
test system and associated SOP have already undergone external PS-based validation for 
skin corrosion testing and the epiCS test method has been included in OECD TG431 on in 
vitro skin corrosion testing based on RhE (OECD TG431). The test method for skin irritation 
testing had been submitted to EURL ECVAM already in 2009 in view of assessing 
compliance of the test system / protocol with regard to the specifications outlined in the PS 
(essential test method components). After confirmation of compliance by EURL ECVAM, the 
submitter organised a ring trial involving three laboratories from industry, including one 
from overseas (US) and one naïve one (i.e. no prior experience with using RhE-based test 
methods). The study, submitted in 2011, showed that the test method fulfilled the 
acceptance criteria of the PS with regard to predictive capacity. However, problems were 
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noted with regard to between-laboratory and, mainly, within laboratory reproducibility, in 
particular in the naïve laboratory. These were probably related to the fact that no 
training/transfer had been organised prior to conducting the ring trial. Additionally, in case 
of the US laboratory, issues with the shipment of the tissue kits may have impacted on the 
results. Following additional testing to address these issues (submitted in 2013), the test 
method has entered ESAC peer review in early 2014. The review is expected to be finalised 
in 2Q 2014. 
The OsREP test method employs an "open source" concept. The protocol underlying OsREP 
was originally developed by Poumay et al. and has been published without any restrictions 
(Poumay et al., 2004). The "open source" concept is intended to utilise this protocol in 
conjunction with information on the evaluation / validated of the protocol: all necessary 
information on both the production and maintenance of OS-Rep (i.e. the relevant SOPs) will 
be free of any restrictions (e.g. patents or other intellectual property rights). Thus, all 
interested users (e.g. in academia, in research or contract-research organisations) will be 
able to reconstruct the RhE test system in their facilities and use the test system either in 
association with the relevant protocol for skin irritation testing (i.e. as skin irritation test 
method) or for other purposes (e.g. research and development). This approach is novel to 
an area of complex tissue-engineered test systems which, so far, are all manufactured and 
quality-controlled by the original test method producers selling batch-controlled tissue kits 
with elements that are protected by intellectual property rights. EURL ECVAM is monitoring 
this development. In particular the issues of (1) transferability of the reconstructed model 
and the implementation of appropriate (2) batch quality control procedures for tissue 
models reconstructed in individual user laboratories need to be carefully evaluated, in 
particular if data are being used for regulatory decision making. This has been 
communicated to the test method developer following evaluation of the test method 
submission. Further the submitter of OsREP intends to produce the test method on an 
automated platform. As epidermal models are still rather costly and could, in addition for 
skin corrosion/irritation purposes possibly also be employed for other endpoints (e.g. 
genotoxicity, percutaneous absorption, skin sensitisation), economical ways of producing 
these tissues may support employing human based tissue models in a variety of 
toxicological assessments. An automated production facility has been installed by 
Fraunhofer Gesellschaft in Germany (see link below) collaborating with the test submitter. 
Important parameters such as batch-release quality and stability as well as robustness 
and relevance of this tissue model remain to be established and independently evaluated. 
At present the submitter, in collaboration with Fraunhofer Gesellschaft7, is carrying out a 
PS-based validation study employing RhE tissue kits produced by automation. EURL ECVAM 
is expecting to receive the results of this study in the near future. 
                                              
7
 http://www.igb.fraunhofer.de/en/competences/tissue-engineering/tissue-models/skin-from-the-factory.html 
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3.6 Test method submission related to eye irritation  
In December 2013, EURL ECVAM received a full submission on the Ocular Irritection® test 
method. The Ocular Irritection® represents a refinement of the former Eytex® method (Kelly, 
1989; Gordon, 1992) following recommendations made by Balls et al. (1995). It predicts 
the ocular hazard effects of chemicals based on the premise that corneal opacity may 
result from the disruptive effects ocular irritants may have on the highly organized 
structure of corneal proteins and carbohydrates. This assay mimics the biochemical 
phenomena of corneal protein denaturation and disruption caused by irritant chemicals 
acting on the cornea. One of the components of the test method is a macromolecular 
reagent composed of a mixture of proteins, glycoproteins, carbohydrates, lipids and low 
molecular weight components. The constituents of the macromolecular reagent combine 
with each other to form a complex macromolecular matrix that mimics the highly ordered 
structure of the transparent cornea. It is believed that irritant chemicals produce a turbidity 
of the macromolecular reagent by promoting protein denaturation, protein unfold and 
change in conformation, which then results in the disruption and disaggregation of the 
highly organized matrix macromolecular reagent matrix. This mechanism is believed to 
mimic the disruptive effects ocular irritants can have on the highly organized structure of 
corneal proteins and carbohydrates, which result in corneal cloudiness / opacity in the in 
vivo Draize eye test. 
The Ocular Irritection® test method underwent an external validation study and is being 
proposed for identifying chemicals not requiring classification for serious eye damage/eye 
irritation (No Category) as well as chemicals inducing serious eye damage (Category 1), 
according to the United Nations Globally Harmonized System of Classification and 
Labelling of Chemicals (UN GHS) (UN, 2013) and in the framework of a Bottom-Up/Top-
Down test strategy (Scott et al., 2010). If, after evaluation by EURL ECVAM, the submission 
is considered to be complete and ready to enter peer-review, it will be submitted to the 
EURL ECVAM Scientific Advisory Committee (ESAC). Peer-review of the Ocular Irritection® 
test method by ESAC is expected to occur in Q3-Q4 2014. 
3.7 Test method submission related to endocrine disruption 
The Yeast Androgen Screen (YAS) assay was submitted to EURL ECVAM towards the end of 
2013 to be considered for an ESAC peer review.  A full validation study, addressing the 
modular approach, had been carried out with 4 laboratories. This assay uses yeast cells 
that are transformed with a human androgen receptor and a lacZ reporter gene.  It 
measures the response towards chemicals with (anti) androgenic potential.   Such assay 
may have potential to be annexed to a future Performance Based Test Guideline (PBTG) 
for Androgen Transactivation Assay (ARTAs).  The submission dossier has been assessed 
by EURL ECVAM in early 2014 and feedback was requested from the submitter for some 
critical procedural aspects prior to continuation of the evaluation. 
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3.8 Test method submission related to acute fish toxicity   
EURL ECVAM received a pre-submission on the RTgill-W1 cell line assay in March 2014.The 
method uses the fish cell line RTgill-W1 derived from rainbow trout gills. Cells are exposed 
to a series of test concentration for 24 h. Cytotoxic effects (EC50 values) are determined 
by measuring the cell viability using three fluorescent dyes (AlamarBlue for cellular 
metabolic activity, 5-carboxyfluorescein diacetate acetoxymethyl ester for cell membrane 
integrity and Neutral Red for lysosomal membrane integrity testing). Cell viability of the 
exposed cells is expressed in % of the control cells. The assessment of the pre-submission 
is ongoing; more information on the method is available in Tanneberger et al (2013). 
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4. Validation of Alternative Methods 
4.1 On-going and finalised validation studies  
4.1.1 Endocrine Disruption  
At OECD level, there is an ongoing activity towards OECD performance based test 
guidelines (PBTG) for estrogen receptor transactivation assays (ERTAs) and androgen 
receptor transactivation assays (ARTAs).  PBTG 455 for the detection of estrogen receptor 
agonists and PBTG 457 for the detection of estrogen agonists and antagonists were both 
adopted in 2012 while a proposal for a PBTG for the detection of androgen receptor 
agonists and antagonists was submitted to the OECD and included in the OECD work plan 
in 2013. 
The AR-CALUX method is an androgen receptor transactivation assay (ARTA) for the 
detection of substances with androgenic properties.  Such substances can bind to the 
androgen receptors and activate (agonist) or block (anti-agonist) cellular responses within 
the endocrine system.  Once validated, this assay in conjunction with other similar assays 
(e.g. the Japanese EcoScreen assay) will contribute towards an OECD PBTG for androgen 
receptor transactivation assays. It is based on the use of osteosarcoma cells transfected 
with the cDNA of a human androgen receptor and the androgen responsive elements 
(AREs) coupled to a luciferase reporter gene (AR-CALUX®).  Response towards substances 
with androgenic activity is hence easily evaluated via the measurement of emitted light.   
The method was accepted to enter a EURL ECVAM validation study in 2012.  A multi-study 
validation trial is scheduled for 2014 and the European Union Network of laboratories for 
the Validation of Alternative Methods (EU-NETVAL) will be involved in this exercise for the 
first time.  Three test facilities will be selected and after approval by the Member States 
via the National Contact Points (NCPs), they will participate in the multi-study validation 
trial.  
A validation study on a transactivation assay that detects chemicals with (anti-) estrogenic 
potential using MELN cells is still ongoing. The cell line used is the MCF-7 human breast 
cancer cell line, that has been stably transfected with an estrogen responsive reporter 
system.  The MCF-7 cells express endogenously the estrogen receptor. The first part of the 
validation study was completed in 2012 with an assessment of the reliability 
(transferability and within and between laboratory reproducibility) for agonist and 
antagonist manual protocols in three laboratories for 16 chemicals. A second step to assess 
relevance (predictive capacity) on a wider set of chemicals in one laboratory by transferring 
the protocol to an inter-plate format on the robotic platform was supported by the OECD's 
non-animal Validation Management Group. Transfer of the agonist protocol to inter-plate 
HTS format (robotic platform) for 16 non-coded chemicals followed by the testing of 22 
coded chemicals from the PBTG OECD 455 Performance Standards has been completed and 
good accuracy (i.e. good prediction of negatives and positives) was obtained but the 
induction factor was low. The next step is to proceed in the same manner for the antagonist 
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protocol using the reference chemicals from the performance standards of the OECD TG 457 
(ERTA for antagonist based on BG1 Luc cells), provided that a new batch of cells can be 
obtained which can respond with a suitably high induction factor.  
4.1.2 Cytochrome P450 Induction  
Cytochrome P450s (CYP) are Phase I biotransformation enzymes and have a high 
prevalence in biotransformation of both endogenous and exogenous xenobiotics. Exposure 
to xenobiotics can lead to the induction of CYP enzymes. EURL ECVAM has carried out a 
multi-study validation trial in order to assess reliability and relevance of two CYP induction 
in vitro methods, each of them evaluating the induction of enzymatic activity of four CYP 
enzymes (CYP1A2, CYP2B6, CYP2C9 and CYP3A4). The human CYP induction method 
project was included in the OECD work plan in 2013.  
The human in vitro CYP validation project had two main objectives: 
A. Assess the transferability, the reproducibility (within and between-laboratory) of 
two human CYP induction-in vitro methods, by evaluating the induction of four CYP enzyme 
activities (CYP1A2, CYP2B6, CYP2C9, CYP3A4). The two in vitro methods use the 
metabolically competent test systems: 
 cryopreserved human HepaRG cells (cryoHepaRG) (1) 
 cryopreserved human primary hepatocytes (cryoheps) (2, 3) 
B. Assess the predictive capacity using human CYP induction in vivo reference data. 
The CYP induction validation project compares two human derived metabolically competent 
test systems using test items for which in vivo human CYP induction data are available. 
The in vitro method simulates the human in vivo method, by means of using a cocktail 
approach.  The Karolinska cocktail was indeed developed to investigate CYP activities of 
different CYPs in vivo in humans (4). Later, a cocktail approach was developed to 
determine, in the same experiment, on in vitro human hepatic test systems, the induction 
of different important human CYP isoforms. In this project, this in vitro methodology was 
used to assess the potential of 13 blind-coded test items to induce 
CYP1A2,CYP2B6,CYP2C9,CYP3A4, using four CYP selective probes (phenacetin, midazolam, 
diclofenac and bupropion). The biotransformed CYP products have been measured with 
analytical method (LC/MS-MS),  
During the validation project, the two human CYP induction in vitro methods have been 
successfully transferred by the lead laboratories to the participating laboratories. The in 
vitro methods can be performed in any modern analytical laboratory and with minimum 
standards in cell culture (Good Cell Culture Practice). Experienced personnel can readily be 
trained in the test methods. The test definition/description aspects of the SOPs are clearly 
written, the execution of the experimental steps and the data analysis can be performed 
without difficulties. All apparatus and reagents needed for the execution of the two human 
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CYP induction in vitro methods are readily commercially available. The cryoHepaRG® cells 
are nowadays available from different suppliers in Europe, USA, Japan and Brazil. 
Based on the data generated during the project, all the different laboratories produced the 
same induction classification (potent/weak inducer, non-inducer) of blind-coded test items 
when performing the experiment with the same batch. 66 % of the experiments with the 
human CYP cryoHepaRG cell line induction in vitro method and 55% of the experiments 
with human CYP cryoheps induction in vitro method were judged to give the same induction 
class in all laboratories and at least 2 out of three laboratories for both human CYP 
induction in vitro methods were concordant in >90% of the experiments.  
The cryoHepaRG CYP induction in vitro method showed higher reproducibility for the 4 CYPS 
under investigation compared to cryoheps CYP induction in vitro method when using for the 
evaluation the same batches. The highest reproducibility value was observed for CYP3A4 
(all batches ≥ 90%). 
At least qualitatively, CYP1A2-, 2B6- and 3A4- selective probe activities performed as 
expected in both in vitro methods both for the data generated with model inducers 
(rifampicin, phenobarbital and beta-napthoflavone at defined concentration) and with the 
blind-coded test items evaluated at different concentrations. CYP2C9- selective probe 
activity was relative high in both test systems and overall induction responses remained 
quite low. The weak induction of CYP2C9 in all conducted experiments reflects the clinical 
situation. In clinical studies CYP2C9 induction by rifampicin is much lower than CYP3A4 
induction. For this reason FDA, EMA and the pharmaceutical industry excluded CYP2C9 
induction assessment from the induction battery. Furthermore, it is considered to be a 
minor problem and always secondary to induction of CYP3A4. 
Data generated during the project give clear indications that the human CYP cryoHepaRG 
cell line induction in vitro method and the human cryopreserved primary hepatocytes 
induction in vitro method are relatively similar in their ability to detect and classify 
substances in terms of CYP1A2, CYP2B6, CYP3A4 and CYP2C9 induction. The overall 
classifications of the blind-coded test items on the basis of the two in vitro methods are in 
line with the in vivo knowledge on classification of these test items. 
The results indicated that human cryoHepaRG cells CYP induction in vitro method showed 
100% sensitivity and specificity for the prediction of CYP1A2, CYP2B6 and CYP3A induction 
based on the results from the blind-coded test items used in the present study. The human 
cryoheps CYP induction in vitro method also showed 100% sensitivity and specificity for 
CYP2B6 and CYP3A induction. However, the human cryoheps CYP induction in vitro method 
showed only 25% sensitivity for prediction of CYP1A2 induction since the method failed to 
predict induction of three test items known to induce CYP1A2 in vivo. The human cryoheps 
CYP induction in vitro method showed 100% specificity since this method predicted all 
CYP1A2 non-inducers to be negative. 
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Because blind-coded test items and reference inducers (except for the positive CYP1A2 
control beta-naphthoflavone) and non-inducers were pharmaceuticals, the described study 
design provides direct evidence on the applicability domain (pharmaceuticals). However, 
since the CYP induction method is based on xenobiotic-nuclear receptor binding, 
dimerization, activation of DNA binding domain and enhanced transcription of the target 
gene, any class of compounds that can interact with such receptors is predicted to be 
qualified to be used in the in vitro human CYP induction methods. 
4.1.3 Eye Irritation  
A prospective validation study of two in vitro test methods using Reconstructed human 
Tissue (RhT) models (MatTek EpiOcular™ and SkinEthic™ Human Corneal Epithelium (HCE)) 
for the detection of chemical induced serious eye damage/eye irritation, has been 
conducted by EURL ECVAM and Cosmetics Europe - The Personal Care Association. Pre-
validation studies with both test methods have served to optimise protocols and refine 
prediction models, and were able to show that both test methods are able to predict ocular 
toxicity properties of test substances with a high degree of accuracy, approximately 80% 
overall. The Eye Irritation Validation Study (EIVS), co-sponsored by EURL ECVAM and 
Cosmetics Europe, evaluated the validity (relevance and reliability) of these two RhT test 
methods to discriminate chemicals not requiring classification for serious eye damage/eye 
irritancy (No Category) from chemicals requiring classification and labelling (Category 1 
and Category 2) according to the United Nations Globally Harmonized System of 
Classification and Labelling of Chemicals (UN GHS) and as implemented by the EU 
Classification, Labelling and Packaging regulation (EU CLP) (UN, 2013; EC, 2008). These 
RhT test methods are not intended to differentiate between UN GHS/EU CLP Category 1 
(serious eye damage) and UN GHS/EU CLP Category 2 (eye irritation). This differentiation 
would be left to another tier of a test strategy as described e.g., by Scott et al. (2010). The 
EIVS has been undertaken in accordance with the principles and criteria documented in the 
OECD Guidance Document on the Validation and International Acceptance of New or 
Updated Test Methods for Hazard Assessment (No. 34, OECD, 2005) and according to the 
Modular Approach to validation (Hartung et al., 2004). 
The protocols assessed were the original EpiOcular™ Eye Irritation Test (EIT) protocol for 
liquid chemicals, the original EpiOcular™ EIT protocol for solid chemicals, an EpiOcular™ EIT 
optimised protocol for solid chemicals, the SkinEthic™ HCE Short-time Exposure (SE) 
protocol, the SkinEthic™ HCE Long-time Exposure (LE) protocol, and the SkinEthic™ HCE test 
strategy combining the SE and LE protocols as well as the Eye irritation Peptide Reactivity 
Assay (EPRA). Two prediction models, using 50% or 60% mean tissue viability as the 
threshold differentiating classified (UN GHS Cat. 1 and Cat. 2) chemicals (mean tissue 
viability ≤ 50% or 60%) from non-classified (UN GHS No Cat.) chemicals (mean tissue 
viability > 50% or 60%), were evaluated with each of the EpiOcular™ EIT protocols, while a 
single prediction model using a 50% mean tissue viability cut-off was evaluated with the 
SkinEthic™ HCE SE, LE and test strategy. 
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EIVS included a statistically sufficient number of chemicals, supported by complete and 
quality assured in vivo Draize eye test data, for comparative evaluation of results. A total 
of 104 selected test chemicals (52 liquids and 52 solids) were distributed as identity coded 
aliquots for blind ring trial testing as three runs in three laboratories for both test methods. 
Following the ring trial, the 52 solid chemicals were re-tested, with an additional 8 others 
newly selected (all identity coded i.e., blind testing) in three runs in one laboratory, for 
validation of an optimised EpiOcular™ EIT solid chemicals protocol. 
EpiOcular™ EIT 
Three independent laboratories participated in the validation of EpiOcular™ EIT, two 
European, i.e. the lead laboratory and a naïve laboratory, and one in the US. All the 
participating laboratories were able to demonstrate their proficiency in performing the 
EpiOcular™ EIT and readiness to enter the formal validation study following training and 
transferability studies. The validation study of EpiOcular™ EIT proved very effective and 
efficient due to a near complete dataset being generated with negligible re-testing 
necessary. 
The EpiOcular™ EIT test method was found to be highly reproducible. The within-laboratory 
reproducibility (WLR) (93.6% and 95.2% concordance of classifications for the 50% and 
60% cut-offs analysed in this study, respectively) and the between-laboratory 
reproducibility (BLR) (91.3% and 93.3% concordance of classifications for the 50% and 
60% cut-offs analysed in this study, respectively) were significantly above the acceptance 
criteria set by the Validation Management Group (VMG) (WLR ≥ 85% and BLR ≥ 80%). 
Taking 60% mean viability as the prediction model threshold differentiating classified (UN 
GHS Cat. 1 and Cat. 2) from non-classified (UN GHS No Cat.) chemicals, the overall 
accuracy (79.0%) and specificity (70.5%) were ‘definitely acceptable’ according to the 
acceptance criteria as defined by the VMG (overall accuracy ≥ 75%; specificity ≥ 60%), 
whereas the sensitivity (87.6%) was between the limits of ‘definitely unacceptable’ (< 
80%) and ‘definitely acceptable’ (≥ 90%). Considering only the liquid chemicals, the test 
method fulfilled all of the ‘definitely acceptable’ criteria (overall accuracy of 81.9%; 
sensitivity of 98.3%; specificity of 66.7%). For the solid chemicals both the overall 
accuracy (75.9%) and the specificity (74.8%) were ‘definitely acceptable’, whereas the 
sensitivity (76.9%) was ‘definitely unacceptable’. Six chemicals were under-predicted based 
on the mode of all predictions, of which one was classified in vivo as Category 1. Taking 
50% mean viability as the prediction model threshold differentiating classified (UN GHS 
Cat. 1 and Cat. 2) from non-classified (UN GHS No Cat.) chemicals, the overall accuracy 
(77.9%) and specificity (74.5%) were ‘definitely acceptable’ according to the acceptance 
criteria defined by the VMG (overall accuracy ≥ 75%; specificity ≥ 60%), whereas the 
sensitivity (81.4%) was still between the limits of ‘definitely unacceptable’ (< 80%) and 
‘definitely acceptable’ (≥ 90%). Again, considering only the liquid chemicals, the test 
method fulfilled all of the ‘definitely acceptable’ criteria (overall accuracy of 82.5%; 
sensitivity of 96.2%; specificity of 69.8%), while for the solid chemicals only the specificity 
(79.7%) was ‘definitely acceptable’. The overall accuracy (73.0%) fell short of ‘definitely 
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acceptable’ (≥ 75%) but surpassed ‘definitely unacceptable’ (< 65%), while the sensitivity 
(66.7%) was ‘definitely unacceptable’. 
Analysis of the EIVS data for solid chemicals indicated scope for improvement through a 
balanced increase in sensitivity with decrease in specificity to attain a compromise of 
sensitivity ≥ 90% with specificity maintained ≥ 60%. Optimisation of the EpiOcular™ EIT 
solids protocol was therefore conducted and follow-up validation of an optimised protocol 
with increased exposure time was performed. The validation of the EpiOcular™ EIT 
optimised solids protocol was conducted with the original 52 EIVS solid chemicals plus an 
extra 8. The post-optimisation validation of the EpiOcular™ EIT optimised solid chemicals 
protocol took place in the lead laboratory for EpiOcular™ EIT in the original validation study. 
The EpiOcular™ EIT optimised solid chemicals protocol was found to be at least as 
reproducible as the original solid chemicals protocol, with 93.2% and 96.6% concordance 
of classifications (based on 59 chemicals) being obtained by the lead laboratory with the 
optimised protocol for the 50% and 60% cut-offs analysed in this study, respectively, as 
compared to 92.0% and 94.0% obtained by the same laboratory with the original protocol 
(based on 50 chemicals). Forty nine (49) chemicals are common to the two datasets. If 
only these are considered in the calculations, the concordance of classifications obtained 
were 91.8% (50% cut-off) and 95.9% (60% cut-off) for the optimised protocol and 91.8% 
(50% cut-off) and 93.9% (60% cut-off) for the original protocol. The within-laboratory 
reproducibility (WLR) of the EpiOcular™ EIT optimised solid chemicals protocol was thus 
significantly above the acceptance criterion set by the VMG (WLR ≥ 85%). Further BLR 
evaluation was identified, by the core VMG, to be unnecessary given the previous good 
reproducibility of the EpiOcular™ EIT test method, and a similar (or even slightly better) 
WLR observed for the optimised solids protocol as compared to the original protocol. With 
the increased exposure time in the optimised solid chemicals protocol, a stronger 
separation between irritants and non-irritants in the viability scale was observed as 
compared to the original protocol, which is expected to improve the reproducibility of the 
test method. 
Taking 60% mean viability as the prediction model threshold differentiating classified (UN 
GHS Cat. 1 and Cat. 2) from non-classified (UN GHS No Cat.) chemicals, the overall 
accuracy (78.0%), the specificity (60.7%) and the sensitivity (93.5%) were all ‘definitely 
acceptable’ according to the acceptance criteria as defined by the VMG (overall accuracy ≥ 
75%; specificity ≥ 60%; sensitivity ≥ 90%). 
Taking 50% mean viability as the prediction model threshold differentiating classified (UN 
GHS Cat. 1 and Cat. 2) from non-classified (UN GHS No Cat.) chemicals, the overall 
accuracy (76.8%) and the specificity (64.3%) were ‘definitely acceptable’ according to the 
acceptance criteria defined by the VMG, whereas the sensitivity (88.2%) was between the 
limits of ‘definitely unacceptable’ (< 80%) and ‘definitely acceptable’ (≥ 90%), but very 
close to being ‘definitely acceptable’. 
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The 60% cut-off was considered to be better than the 50% cut-off because it resulted in a 
better sensitivity and generated less false negatives based on the mode of all predictions, 
with similar overall accuracy. The overall predictive capacity of EpiOcular™ EIT considering 
a combination of the data obtained for the liquid chemicals protocol with the data obtained 
using the optimised solid chemicals protocol, and a cut-off of 60%, consists of a sensitivity 
of 95.7%, a specificity of 63.0% and an overall accuracy of 79.7%. On this basis, all of the 
acceptance criteria defined by the VMG are met. Two out of 57 chemicals (2 solid Cat. 2B 
chemicals) were under-predicted (false negatives) and 20 out of 54 chemicals (9 liquids 
and 11 solids) were over-predicted (false positives) based on the mode of all predictions. 
SkinEthic™ HCE 
Three independent laboratories participated in the validation of SkinEthic™ HCE, two 
European, i.e. the test method developer and the lead laboratory and a naïve laboratory, 
and one in the US, a second naïve laboratory. All the participating laboratories were able to 
demonstrate their proficiency in performing the SkinEthic™ HCE and readiness to enter the 
formal validation study following training and transferability studies. The validation study 
of the SkinEthic™ HCE proved to be very straightforward due to a near complete dataset 
being generated with negligible re-testing performed. 
The SkinEthic™ HCE test method was found to be highly reproducible. The WLR (93.9% and 
95.5% concordance of classifications for the SE and LE, respectively) and the BLR (92.3% 
concordance of classifications for both the SE and the LE protocols) were significantly 
above the acceptance criteria set by the VMG (WLR ≥ 85% and BLR ≥ 80%). 
The only prediction model that was evaluated used a mean viability of 50% as the 
threshold differentiating classified (UN GHS Cat. 1 and Cat. 2) from non-classified (UN GHS 
No Cat.) chemicals. The specificity of this prediction model was found to be ‘definitely 
acceptable’ according to the acceptance criterion defined by the VMG (≥ 60%), regardless 
of the protocol or strategy (SE: 88.5%; LE: 65.5%; test strategy: 77.1%). The sensitivity was 
on the other hand ‘definitely unacceptable’ (< 80%) according to the same acceptance 
criteria (SE: 42.7%; LE: 71.6%; test strategy: 54.5%). The overall accuracy was between the 
limits of ‘definitely unacceptable’ (< 65%) and ‘definitely acceptable’ (≥ 75%) (SE: 65.6%; 
LE: 68.6%; test strategy: 65.8%). Moreover, of the 30 chemicals that were under-predicted 
by SE and of the 15 that were under-predicted by LE based on the mode of all predictions, 
14 and 5, respectively, were classified in vivo as Category 1, which was also ‘definitely 
unacceptable’. Use of the SkinEthic™ HCE test strategy also led to 10 Category 1 chemicals 
being under-predicted as non-irritants (based on the mode of all predictions). Based on 
these values neither of the two SkinEthic™ HCE protocols (SE or LE) was considered valid. 
The use of EPRA to orient chemicals to the LE (non-reactive) or SE (reactive) protocol 
(SkinEthic™ HCE test strategy) was also considered not valid. 
Nevertheless, analysis of the data for the SkinEthic™ HCE indicated scope for improvement. 
Further optimisation has therefore been recommended for the SkinEthic™ HCE test method 
considering different protocols for liquid chemicals and solid chemicals, as with EpiOcular™ 
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EIT. Optimisation of the SkinEthic™ HCE test method is currently being conducted by the 
test method developer and further validation is foreseen in the near future. 
4.1.4 Genotoxicity  
Micronucleus test and comet assay in reconstructed skin models  
The validation of methods for genotoxicity testing in reconstructed human 3D skin models, 
i.e. the micronucleus test and the comet assay, is still ongoing (Aardema et al., 2010; Reus 
et al., 2013). The validation of the micronucleus test in 3D epidermis model, led by 
Cosmetics Europe, has entered in its final experimental phase; while the between-
laboratory reproducibility of the comet assay in full-thickness skin models, a joint effort 
between Cosmetics Europe and the German Federal Institute for Risk Assessment (BfR), is 
under evaluation.  
Hen's egg test for micronucleus induction (HET-MN) 
The hen's egg test for micronucleus induction (HET-MN; Wolf et al., 2008) has been 
proposed as a follow-up test method for in vitro positives. The HET-MN combines the use 
of the commonly accepted genetic endpoint “formation of micronuclei” with the well-
characterised and complex model of the incubated hen's egg, which enables metabolic 
activation, elimination and excretion of xenobiotics, including those that are mutagens or 
pro-mutagens. The transferability and within and between laboratory reproducibility are 
currently being evaluated by a German consortium (Greywe et al., 2012). 
4.1.5 Ongoing Validation Studies for Vaccine Testing - Biological Standardisation 
Programme 
Most of the validation studies on alternative methods for vaccine testing are carried out 
within the framework of the Biological Standardisation Programme (BSP) of the European 
Directorate for the Quality of Medicines & HealthCare (EDQM; Council of Europe) and co-
sponsored by the European Commission. Several validation studies on alternative methods 
for potency and safety testing of various vaccines for human and veterinary use are 
currently ongoing or planned to start in 2014 (e.g. a serological assay for the potency 
testing of whole-cell pertussis vaccines, a serological assay for the potency testing of 
rabies vaccines; an in vitro method for the safety testing of tetanus vaccines; in vitro 
methods for potency testing of diphtheria and tetanus vaccines). More information of the 
BSP, its background and work programme is available at http://www.edqm.eu/en/Biological-
Standardisation-Programme-mission-60.html.  
In this context, three projects should be highlighted which are currently ongoing and aim at 
standardising methods to become ready for full validation within the BSP: in vitro methods 
for safety testing of acellular pertussis vaccines (Bache et al, 2012; Isbrucker et al, 2014), 
in vitro methods for in process control of clostridial vaccines and in vitro methods for the 
potency testing of rabies vaccines (see paragraph 5.5.2.2 EPAA projects). These are joint 
projects involving manufacturers and Official Medicines Control Laboratories. 
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4.2 Peer reviews by the EURL ECVAM Scientific Advisory Committee 
4.2.1 Renewal of ESAC in 2013 
The ESAC is managed and coordinated in agreement principles and practices of the 
Commission relating to external expert advice for policy conception, monitoring and update. 
A key document is the Commission communication on "The collection & use of expertise by 
the Commission: Principles and Guidelines. Improving the knowledge base for better 
policies" (EC, 2002). These guidelines have been taken up in ESAC's Rules of Procedure 
which describe the principles and mode of operation of the committee. An important 
element of ESAC is that members should not represent their employing organisations, but 
participate in their personal capacity as scientists. Moreover, members have to declare their 
interests, and sign declarations of commitment (to the Committee's work in the interest of 
the public good) and confidentiality (to protect legitimate interests of test method 
submitters). Moreover, EURL ECVAM uses a consistent workflow based on formal "EURL 
ECVAM requests for ESAC advice" outlining the background to the topic, the objective and 
detailed charge questions as well as timelines and deliverables. One important element of 
ESAC's functioning is the use of specialised ESAC Working Groups, which draw also on the 
expertise of external scientist proposed by ESAC members, EURL ECVAM or nominated by 
ICATM partners.  
Another important element is the principle of 'plurality', i.e. the need to listen to as wide as 
possible a variety of experts. Since the ESAC for logistical and budgetary reasons needs to 
have a limited number of members (n=15), EURL ECVAM is implementing this principle via a 
regular renewal of the committee: according to the Rules of Procedure, the term of office of 
the ESAC is three years. Since ESAC had been last renewed in 2009, EURL ECVAM published 
an open call for the expression of interest from December 2012 to January 2013. This call 
was modelled closely along the one from 2009 but addressing further aspects of ECVAM's 
work (now referred to as EURL ECVAM) such as test method development and modern 
chemical safety assessment science. The open call was directed at scientists active in the 
fields of life sciences, medicine, toxicology, chemistry and various technical competences. 
Applications from 42 scientists were received. These were pooled with candidatures on the 
reserve list of the 2009 call (n=32) as well as expressions of interest of current ESAC 
members regarding a second term (n=11). Therefore, a total of 85 applications / expressions 
of interest had to be evaluated.  
A Selection Committee (SC) consisting of two external scientists with profound knowledge 
of the field plus two staff members of EURL ECVAM had been set up, charged with 
evaluating all eligible applications and expressions of interest in view of developing a 
shortlist of about 30 candidates. The SC was asked to identify, based on this shortlist, 15 
candidates particularly suited for nomination by the Director of the Institute. The SC worked 
on the basis of a guidance document outlining objective and transparent eligibility and 
selection criteria and providing guidance on how to apply these in a semi-quantitative 
manner based on the intrinsic weighing of six selection criteria. Following assessment of the 
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applications against the pre-defined criteria, the committee shortlisted 15 scientists. The 
shortlist was based predominantly on considerations of scientific excellence (as for the 
shortlist) but weight was also given to aspects of gender and geographical balance as well as 
the right blend of experience versus fresh ideas that potential members would bring to the 
table. The 15 shortlisted candidates were appointed for membership of ESAC by the 
Director of the JRC's Institute for Health and Consumer Protection (hosting EURL ECVAM) in 
summer 2013.  
The first meeting of the renewed ESAC was held in June 2013 and served to kick-off the 
activities of the new committee and introduce its members with the necessary information 
on EURL ECVAM's mission, projects and activities as well as the principles and processes of 
ESAC Scientific Peer Reviews. During this first meeting, the ESAC decided, following a 
proposal of EURL ECVAM, to set up three ESAC Working Groups (WGs) dedicated with 
preparing detailed scientific peer reviews for consideration by ESAC. 
4.2.2 ESAC Scientific Peer Reviews  
In 2012 ESAC finalised four scientific peer reviews of validation studies which led to EURL 
ECVAM recommendations in 2013 and 2014 (see 4.3). These concerned:  
(1) The EURL ECVAM-coordinated follow-up study on the 3T3 NRU assay to support 
identification of substances not requiring classification as acute oral toxicants. 
 
(2) The Direct Peptide Reactivity Assay (DPRA), an in chemico method for assessing the 
skin sensitisation potential of chemicals by determining their reactivity towards 
synthetic Lysin and Cystein-containing peptides. 
 
(3)  The Bhas Cell Transformation Assay (Bhas CTA) for assessing the potential 
carcinogenicity of substances by assessing the downstream morphological 
phenomena associated with the malignant transformation of cells.  
 
(4) The KeratinoSensTM assay for assessing the skin sensitisation potential of chemicals 
by measuring the activation of the Keap1-Nrf2-ARE cytoprotective pathway in a 
human keratinocytes-derived cell line (HaCaT).  
In 2013 ESAC finalised the scientific peer review on the Zebrafish Embryo Toxicity Test 
(ZFET) for acute fish toxicity testing. The ESAC found that the ZFET is a reproducible 
method that, based on a retrospective data set evaluating through orthogonal regression 
the correlation between (Z)FET data and data from acute and juvenile fish of various 
species, appears to provide information equivalent to that generated by the standardised 
acute fish toxicity test (i.e. OECD TG 203). At its spring meeting in 2014 ESAC finalised the 
scientific peer review of the human Cell Line Activation Test (h-CLAT) for skin sensitisation 
testing. The EURL ECVAM Recommendation on the test method is currently in preparation 
and will undergo a restricted consultation round  (i.e. by PARERE, ESTAF and ICATM) in 
summer 2014. 
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Further, in 2014, ESAC has started with the scientific peer review of EURL ECVAM-
coordinated validation studies on Eye Irritation and on two human hepatic test systems for 
measuring the induction of Cytochrome P 450 enzymes (CYP). The reviews are expected to 
be finalised by summer 2014. The review of the MELN assay (an Estrogen Receptor 
Transactivation Assay, ERTA) had to be postponed as the validation data could not be 
generated as planned due to problems with the test system. 
 
4.3 EURL ECVAM Recommendations 
Since 2011, the final product of the EURL ECVAM validation process are the EURL ECVAM 
recommendations8. These are based on the validation reports, the ESAC peer review and 
the input received during consultation rounds with EURL ECVAM’s network of regulators 
(PARERE-Preliminary Assessment of Regulatory Relevance), the ECVAM Stakeholder Forum 
(ESTAF), the International Cooperation on Alternative Test Method (ICATM) and the general 
public. Also the test method submitter has a right to comment on the EURL 
Recommendation prior to its publication. 
4.3.1 EURL ECVAM recommendation on the 3T3 Neutral Red Uptake (3T3 
NRU) Cytotoxicity Assay 
In 2013, EURL ECVAM published a recommendation on the 3T3 NRU test method for the 
identification of substances not requiring classification for acute oral toxicity (EC EURL 
ECVAM 2013).  EURL ECVAM fully endorsed the ESAC opinion and concluded that the 3T3 
NRU test method may prove a valuable component of a Weight of Evidence approaches 
(WoE) or Integrated Testing Strategies (ITS) for supporting hazard identification and safety 
assessment in agreement with the EU CLP Regulation and international regulatory 
schemes implementing the upper threshold of UN GHS Category 4 as the cut-off for non-
classification of substances (i.e.  oral LD50 > 2000 mg/kg b.w). In particular, data from the 
3T3 NRU assay may constitute an information source within a WoE approach under the 
provisions of the REACH Regulation (Annex XI, 1.2) potentially supporting conclusions on 
absence of acute oral toxicity of industrial chemicals. Considering its limitations, namely 
lack of metabolic competence associated with Phase I and Phase II biotransformation and 
mechanistic relevance limited to basal cytotoxicity, EURL ECVAM recommended that results 
derived from the 3T3 NRU test method should always be used in combination with other 
information sources to build confidence in the decision not to classify a substance for 
acute oral toxicity. Thus, efforts need to be invested in the identification of relevant and 
complementary information as well as gathering and organising mode-of-action 
knowledge related to this endpoint since this would be very valuable in the design and 
validation of integrated prediction methods. 
                                              
8
 for more information: http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/eurl-ecvams-validation-process) 
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4.3.2 EURL ECVAM recommendation on the DPRA  
EURL ECVAM fully endorsed the ESAC opinion on the EURL ECVAM-coordinated validation 
study of the DPRA and concluded that the DPRA is a mechanistically relevant test method 
that can contribute to the assessment of the skin sensitisation potential of chemicals when 
used within integrated approaches such as WOE approaches or ITS  (EC EURL ECVAM 
2013a). The EURL ECVAM study showed that the DPRA is a transferable test method and 
sufficiently reproducible within and between laboratories. A complete evaluation of the 
predictive capacity of the DPRA was outside the scope of the ECVAM validation study since 
the test method is not proposed as a stand-alone full replacement, nevertheless the 
accuracy in discriminating between sensitisers and non-sensitisers calculated with the set 
of chemicals tested in the validation study was 86% which is in agreement with published 
information from previous studies. The Recommendation acknowledged that in addition to 
supporting the discrimination between sensitisers and non-sensitisers, DPRA information 
may also have the potential to contribute to potency assessment. However, additional work 
is still required to determine how DPRA results can be exploited within integrated 
approaches for potency prediction using preferably human data. EURL ECVAM 
recommended that in consideration of the fact that the DPRA is covering only one single 
biological mechanism of the skin sensitisation pathway and because of DPRA's known 
limitations such as the lack of metabolic capacity, DPRA information should always be used 
in combination with other information sources. EURL ECVAM recommended the 
development of an OECD Test Guideline for the DPRA. 
4.3.3 EURL ECVAM recommendation on the KeratinoSens™ 
EURL ECVAM fully agreed with the ESAC opinion on the Givaudan-coordinated validation 
study of the KeratinoSens™ test method and supplementary information submitted to 
EURL ECVAM and concluded that the test method is mechanistically relevant to be used as 
a valuable component within integrated approaches for skin sensitisation testing (EC EURL 
ECVAM 2014). According to the validation study data the test method has shown to be 
transferable and reproducible within and between laboratories. In the recommendation 
EURL ECVAM acknowledged that the 75% accuracy of the KeratinoSens™ in discriminating 
between sensitisers and non-sensitisers calculated with the data submitted to EURL 
ECVAM is in line with the accuracy values published in the scientific literature indicating the 
usefulness of the method to contribute to the assessment of the skin sensitisation 
potential of chemicals.  EURL ECVAM also acknowledged that concentration-response 
information generated with the KeratinoSens™ may play a role in integrated approaches 
for potency prediction. As in the case of the DPRA, also for the KeratinoSens™, follow up 
work was recommended to better understand how KeratinoSens™ information can support 
potency prediction preferably making use of human data. Given the fact that the test 
method addresses only one single biological mechanism of skin sensitisation and 
considering its known limitations such as the limited metabolic capacity and ability to 
detect only cysteine-reactive chemicals EURL ECVAM recommended the use of the method 
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in combination with other information sources. EURL ECVAM in its recommendation 
supported the development of an OECD Test Guideline for the KeratinoSens™. 
4.3.4 EURL ECVAM recommendation on Bhas42 cell transformation assay (CTA) 
Similar to previously validated in vitro cell transformation assays (CTAs), the CTA in Bhas 
42 cells aims at predicting carcinogenic potential. Based on the results of a validation 
study coordinated by Hadano Research Institute (HRI) Food and Drug Safety Center (FDSC) 
and other published data, the Bhas 42 CTA protocol (including the 6-well and 96-well plate 
versions) was considered to be sufficiently standardised, transferable, reproducible 
between laboratories and relevant to support the identification of potential carcinogenicity 
of substances. Following independent scientific peer review by ESAC and having considered 
the input from regulators, stakeholders, international partners and the general public, EURL 
ECVAM published a recommendation on the Bhas 42 CTA, which concluded that the CTA in 
Bhas 42 cells shows promise for inclusion within weight of evidence or integrated testing 
strategy approaches to assess carcinogenic potential or to support chemical category 
formation and read-across. Thus EURL ECVAM recommends that an OECD Test Guideline 
be developed. In addition, further investigations on the capability of the assay to detect 
tumour promoters would provide useful information on mode of action of carcinogens for 
risk assessment purposes. 
4.3.5 Draft EURL ECVAM recommendation on the Zebrafish Embryo Acute 
Toxicity Test Method (ZFET) 
The draft EURL ECVAM recommendation on the Zebrafish Embryo Acute Toxicity Test 
Method (ZFET) is being finalised and is available for public comments. It concludes that the 
ZFET is transferable and reproducible within and between laboratories as shown in the 
OECD validation study. The comparison of data on 144 chemicals (Belanger et al, 2013) 
demonstrated a strong correlation between fish embryo acute toxicity data (24-120 h 
exposure; mainly Zebrafish) and fish acute toxicity data (96 h; five freshwater species 
recommended in OECD TG 203). Notably, the chemicals covered a broad range of physico-
chemical properties, toxicological modes of action, and sectorial use, e.g. industrial 
chemicals, plant protection products, biocides, and pharmaceuticals. It is therefore 
concluded that the ZFET provides information on acute fish toxicity that can be considered 
comparable to that derived from standard acute fish toxicity tests (e.g. OECD TG203; OECD 
1992) and regulators should consider its use for acute fish toxicity testing whenever 
possible. The use of the ZFET will result in an overall reduction of the numbers of juvenile 
and adult fish required for aquatic toxicity testing.  
As per Article 1(3)(a)(i) of Directive 2010/63/EU (EU 2010) on the protection of animals 
used for scientific purposes, live non-human vertebrate animals including independently 
feeding larval forms are covered by its scope. Zebrafish is generally not considered as 
being capable of independent feeding until 5 days post fertilisation. This is confirmed by 
the Commission Implementing Decision 2012/707/EU (EU 2012) on a common format on 
collection of information on the use of animals for scientific purposes in the EU that states 
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that "Fish should be counted from the stage of being capable of independent feeding 
onward. Zebrafish kept in optimal breeding conditions (approximately + 28°C) should be 
counted 5 days post fertilisation". Considering the foregoing, the embryos in question 
should not be considered as "independently feeding larval forms" within the meaning of the 
Directive 2010/63/EU and therefore the procedure, as far as the embryos are concerned, 
does not fall within its scope. 
4.4 The European Union Network of Laboratories for the Validation of 
Alternative Methods (EU-NETVAL)   
4.4.1 Background and context of EU NETVAL 
The European Union Network of Laboratories for the Validation of Alternative Methods (EU-
NETVAL) mission is to provide support for EURL ECVAM validation studies that serve to 
assess the reliability and relevance of alternative methods that have a potential to replace, 
reduce or refine the use of animals for scientific purposes.   
EU-NETVAL has been established to address some of the provisions of Directive 
2010/63/EU on the protection of animals used for scientific purposes. Article 47 of the 
Directive provides that;  
"1. The Commission and the Member States shall contribute to the development and 
validation of alternative approaches which could provide the same or higher levels 
of information as those obtained in procedures using animals, but which do not 
involve the use of animals or use fewer animals or which entail less painful 
procedures, and they shall take such other steps as they consider appropriate to 
encourage research in this field. 
2. Member States shall assist the Commission in identifying and nominating 
suitable specialised and qualified laboratories to carry out such validation studies. 
3. After consulting the Member States, the Commission shall set the priorities for 
those validation studies and allocate the tasks between the laboratories for carrying 
out those studies.  
4. Member States shall, at national level, ensure the promotion of alternative 
approaches and the dissemination of information thereon."  
In line with Article 48 of the Directive, Annex VII lists the duties and tasks of the EU Reference 
Laboratory, covering inter alia:  
"(a) coordinating and promoting the development and use of alternatives to 
procedures including in the areas of basic and applied research and regulatory 
testing;  
(b) coordinating the validation of alternative approaches at Union level;  
(c) acting as a focal point for the exchange of information on the development of 
alternative approaches;  
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(d) setting up, maintaining and managing public databases and information 
systems on alternative approaches and their state of development;  
(e) promoting dialogue between legislators, regulators, and all relevant 
stakeholders, in particular, industry, biomedical scientists, consumer organisations 
and animal-welfare groups, with a view to the development, validation, regulatory 
acceptance, international recognition, and application of alternative approaches." 
EU-NETVAL will facilitate the EU Reference Laboratory to meet its objectives under Article 48. 
Furthermore, membership in EU NETVAL provides one channel, among others, for both the 
Commission and the Member States to actively contribute to the development and validation of 
alternative approaches as required by the Directive.  
EU-NETVAL is coordinated and supported by EURL ECVAM, in close collaboration with 
Directorate-General for Environment and the National Contact Points (NCPs) for 
implementation of Directive 2010/63/EU on the protection of animals used for scientific 
purposes. Also Directorate-General for Industry and Enterprise who is chair of the Good 
Laboratory Practice EU work group is involved in the activity. 
A Terms of Reference (ToR) of EU-NETVAL has been developed. The ToR outlines the 
legislative anchor, the establishment of the network and the maintenance of its 
membership, tasks of the network members and of EURL ECVAM in support to validation 
studies, the allocation of tasks to the members, and the financing of network activities 
(approved by the National Contact Points of Directive 2010/63/EU on 26/11/2013). The ToR 
was formally approved by the NCPs on 26 November 2013.  
4.4.2 EU-NETVAL establishment 
In 2012, the NCPs for implementation of Directive 2010/63/EU were requested to provide 
a list of candidate laboratories to be assessed for inclusion in EU-NETVAL. In January 2013 
EU-NETVAL drew up a list of Eligibility Criteria previously agreed with NCPs for the 
assessment of candidate members for inclusion in EU-NETVAL. An on-line questionnaire, 
based on these Eligibility Criteria was developed and launched in July 2013. One of the 
eligibility criteria requests the availability of a quality system, preferable Good laboratory 
Practice GLP. Fourty candidate laboratories were provided by the NCPs, who were then 
requested to complete the on-line questionnaire, exclusively made available in March 2013 
for the candidate laboratories proposed by the NCPs, so to assess the suitability of the 
laboratories to be selected as EU-NETVAL members. The replies to the on-line 
questionnaire were then evaluated for their completeness and suitability in accordance 
with the Eligibility Criteria. Of the original 40 laboratories, 14 facilities were selected for 
inclusion in EU-NETVAL. These 14 laboratories were formally appointed to EU-NETVAL on 
the 3rd July 2013. After the selection of the first EU-NETVAL member laboratories, a public 
EURL ECVAM web-call was launched to broaden the competence base and covering more 
EU Member States. Any suitably qualified test laboratories residing in either an EU country, 
EU candidate country or EFTA member country could apply for EU-NETVAL membership. 
Based on this process today there are a total of 26 test facilities within EU-NETVAL (25 
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test facilities from EU Member States plus the European Commission's own in vitro GLP 
test facility operated by EURL ECVAM, who also coordinates the network), selected against 
the pre-defined eligibility criteria and approved by the National Contact Points9. The EU-
NETVAL member test facilities are getting proposals from EURL ECVAM for participation in 
multi-study validation trials.  
The first project that started in 2014 was the generation of experimental data using the in 
vitro AR-CALUX method to support the development of an OECD performance-based test 
guideline and associated performance standards for Androgen Receptor Transactivation 
Assays (ARTA) for the detection of compounds with (anti)androgenic potential (see 4.1.1). 
                                              
9
 http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/eu-netval.   
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5. Promoting the Regulatory Acceptance of Alternative Methods and 
Approaches 
5.1 OECD Test Guideline Programme 
5.1.1 Draft OECD Test Guidelines on DPRA and Keratinosens™ 
EURL ECVAM is leading at the OECD the development of the DPRA test guideline and is co-
leading, together with the Swiss Federal Office of Public Health, the development of the 
KeratinoSens test guideline. Draft test guidelines have been submitted to the OECD in 
November 2013 and underwent revisions following the first commenting round and an 
OECD expert meeting held in February 2014. The DPRA and KeratinoSens test methods 
are proposed in the TGs to be used for supporting the discrimination between sensitisers 
and non-sensitisers within Integrated Approaches for Testing and Assessment (IATA). Their 
potential to inform potency prediction will also need to be evaluated in the context of an 
IATA. The development of an OECD draft test guideline for the h-CLAT is foreseen to be 
undertaken in 2014 under the co-leadership of JaCVAM and EURL ECVAM. 
5.1.2 Draft OECD Test Guideline on SHE and Bhas CTA 
In support to the draft OECD Test Guideline (TG) on cell transformation assays (CTA) in 
Syrian Hamster embryo (SHE) cells, some additional analyses were undertaken in order to 
address comments raised by a few WNT representatives on the modification of data 
interpretation criteria, the equivalence of the SHE CTA performed at pH 6.7 and pH 7.0 and 
the relative sensitivities of the assay to non-genotoxic carcinogens at the two pH 
conditions.  
To address these questions, the following analyses were undertaken: 
Comparison of the results obtained for chemicals tested at both pH 6.7 and 7.0, using re-
analysed data; re-analysis of the results of the Detailed Review Paper (DRP) 31, going back 
to the published literature and applying the draft TG interpretation criteria; determination 
of the performance of the assay based on the old and new interpretation criteria, including 
information regarding non-genotoxic chemicals; categorization of chemicals into genotoxic 
and non-genotoxic; identification of target tumour and carcinogenic mechanism of action 
of non-genotoxic carcinogens. 
A revised TG has been submitted for adoption at the 2014 WNT. There was no consensus 
to approve the revised TG but it was agreed to make the SHE CTA test method available in 
a guidance document (GD), after further revision (including a couple of introductory 
paragraphs on the caveats related to the method) and subsequent WNT review.  
GDs are not covered by Mutual Acceptance of Data (MAD), but it will allow test method 
users to perform  the test method  in a standardised manner.   
The need for the development of an IATA (Integrated Approach to Testing and Assessment) 
was also expressed and it was proposed that a scoping exercise be started and a short 
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paper developed in preparation of a workshop on IATAs to be held in Washington DC in 
November 2014.  
 
A TG was drafted on the BHAS 42 CTA, which underwent a first commenting round. Further 
analyses will need to be undertaken as suggested at the CTA expert meeting held in 
January 2013. After revision of the draft TG, a second commenting round will take place in 
2014. The fate of the draft TG on the Bhas 42 is currently unclear, i.e. it has not yet been 
decided if the draft TG will become a guidance document like the SHE CTA TG. The 
validation report of the test method was endorsed by the WNT in April 2014 and it will be 
declassified and published in June or July 2014 in the OECD Series on Testing and 
Assessment.  
5.1.3 Revision of OECD Test guidelines related to genotoxicity testing 
Existing OECD TGs for in vitro and in vivo genotoxicity testing (TGs 473, 474, 475, 487) 
have been revised according to recent developments and have been adopted (with 
amendments for some of them) by the WNT in 2014. Moreover a TG on the in vivo comet 
assay validated by JaCVAM has also been adopted in 2014.  
5.1.4 Test Guideline on Aquatic Toxicity 
The OECD TG 236 "Fish embryo acute toxicity (FET) test" was adopted by the OECD WNT in 
April 2013 and published in July 2013 (OECD, 2013). EURL ECVAM contributed to the 
development of this TG since 2006 as a member of the relevant OECD expert group and by 
coordinating the validation of the Zebrafish embryo acute toxicity test on behalf of OECD 
(OECD, 2011; OECD, 2012). The standard operating procedure used in the validation study 
formed the basis for the OECD TG 236. 
Other TGs or GDs based on alternative methods were approved at the OECD WNT 26 held 
on 8 to 11 April 2014. They can be found in Annex 1. 
5.1.5 New Projects Submitted to the OECD 
5.1.5.1 EpiOcular™ EIT 
Based on the outcome of the Eye Irritation validation study described in paragraph 4.1.3, a 
Standard Project Submission Form (SPSF) was submitted by the European Commission to 
the OECD for the development of a new OECD Test Guideline, with lead by the European 
Commission Joint Research Centre (EURL ECVAM). The SPSF was discussed and approved 
by the OECD WNT at its 26th meeting on April 8-11, 2014. A new draft Test Guideline on 
the EpiOcular™ EIT for the identification of chemicals not requiring classification for serious 
eye damage/eye irritation will be prepared and submitted to the OECD during Q2-Q3 2014. 
5.1.5.2 In vitro Fish Hepatic Metabolism Test  
Information on accumulation in aquatic organisms is important for understanding the 
behaviour of a compound in the environment. This information is used for hazard 
classification and for the assessment of persistent, bioaccumulative and toxic (PBT) 
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substances. In general, a bioconcentration factor (BCF) is estimated based on various 
prediction techniques as log Kow, (Q)SARs or other computer models, or, if deemed 
necessary, derived from experimental data measured with aquatic species, preferably fish. 
The standard test guideline (OECD TG 305; OECD, 2013) requires at least 108 fish, is 
expensive and time-consuming. Since in silico BCF models are often neglecting the 
contribution of metabolism as a clearance mechanism, they might overestimate the 
bioaccumulative potential of a chemical and, in consequence, might trigger unnecessary in 
vivo tests. Inclusion of biotransformation rates would enhance the reliability of the in silico 
models for BCF prediction. 
The project (proposed by the USA and European Commission) aims at developing a test 
guideline for in vitro methods to determine information on possible biotransformation of 
chemicals in fish. The in vitro fish intrinsic hepatic clearance rates are derived using 
rainbow trout S9 fraction (Johanning et al, 2012) or cryopreserved hepatocytes (Fay et al, 
submitted) and extrapolated to whole-body metabolism rate constant (kMET; 1/h; Nichols et 
al, 2013). It is planned to carry out a multi-laboratory ring trial to assess the reliability, 
transferability, and predictive value of the two in vitro systems within the framework of the 
ILSI HESI project committee "Bioaccumulation" of which EURL ECVAM is a member 
(http://www.hesiglobal.org/i4a/pages/index.cfm?pageid=3319). The project was approved in 
2014 and included in the OECD work plan. 
5.1.5.3 Good In Vitro Method Practice (GIVIMP): Guidance on the implementation of in 
vitro methods within a GLP environment to support regulatory human safety assessment 
of chemicals 
In vitro methods often based on the use of human cells and tissues are submitted to 
international validation bodies (Rispin A. et al 2004; Gupta K. et al, 2005; OECD, 2004). 
Well-designed, robust, reliable in vitro methods that can run in a GLP environment for 
generating data sets are becoming more and more instrumental for supporting regulatory 
decisions.  
GIVIMP will contribute to increased standardisation and international harmonisation in the 
generation of in vitro information on test item safety and will give guidance to obtain a 
high level of data quality based on sound scientific principles to support regulatory human 
safety assessment of chemicals using in vitro methods.   
GIVIMP will also further facilitate the application of the OECD Mutual Acceptance of Data 
Agreement (MAD) for data generated by in vitro methods avoiding as such unnecessary 
duplication of testing by MAD-adherent countries. GIVIMP will take into account the 
requirements of the existing OECD guidelines and advisory documents to ensure that the 
guidance is complementary and 100% in line with these issued documents (OECD, 2004 
and 2005).  
The objectives of this guidance document are:  
(1) To provide a detailed update on today’s state-of-the-art of good practices when 
applying in vitro methods in regulatory human safety assessment of chemicals of 
various kinds;  
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(2) To provide guidance to users and implementers of in vitro methods to help to 
ensure that the Standard Operating Procedures (SOPs) of such methods are well-
designed, robust, well-defined and described and can run in a GLP environment, 
which is essential for use in a regulatory environment;  
(3) To provide guidance on minimum SOP requirements and reporting features to strive 
for more harmonised approaches for today's regulatory needs in the field of human 
safety assessment; 
(4) To describe the key importance of applying Good Cell Culture Practice (Coecke et al., 
(2005)), essential in the identification, authentication and characterisation of the in 
vitro biological model (e.g. test systems such as cell lines, stem cells, primary cells 
and tissues) used in in vitro methods; 
(5) To describe the key importance of applying good test item handling procedures and 
clarify the importance of a clear definition of the in vitro environment that hosts the 
in vitro test system, which is essential for the correct dosing of the test system, and 
for the assessment of test item compatibility with the specific in vitro environment;  
(6) To describe the key importance of applying good experimental design, establishing 
acceptance criteria for in vitro methods, describing equipment requirements 
(including also those based on new technologies and any scientific progress in the 
field of detection methods) and performance standards based on scientific evidence 
from the generated in vitro data sets;  
(7) To describe how International collaborations and networks can help in 
disseminating GIVIMP and the use of the generated data sets for specific regulatory 
applications. GIVIMP will contribute to the use of in vitro method data to support 
regulatory human safety assessment of chemicals by striving that such data are 
being generated in compliance with high quality standards and based on current 
good scientific practices.  
EURL ECVAM will pursue this project with the involvement of EU-NETVAL and other 
relevant European experts with competences in both GLP and good scientific practices in in 
vitro methods. Eventual inclusion of the project within a programme of the OECD in order 
to produce an internationally recognised Guidance Document is under discussion. 
5.2 Guidelines on vaccines 
VICH guidelines - Harmonisation of criteria for waiving of target animal batch safety 
testing of vaccines for veterinary use 
The requirements on batch safety testing differ between the various geographic regions. 
For example, general safety tests for batch release of human and veterinary vaccines are 
no longer required in Europe and have been deleted from European Pharmacopoeia 
monographs several years ago (abnormal toxicity test; Schwanig et al, 1997) or recently 
(target animal batch safety test; EDQM 2012). Since these tests may still be required 
outside of Europe, European manufacturers may need to carry out these tests when 
exporting to third countries. 
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In 2013, the Committee for Medicinal Products for Veterinary Use of the European 
Medicines Agency (EMA, 2013) adopted the guideline on "Harmonization of criteria to waive 
the target animal batch safety testing for inactivated vaccines for veterinary use" (VICH 
GL50). Its implementation (from 1st March 2014 onwards) is a major step towards 
international harmonisation and allows European manufacturers to apply for a waiver of 
the TABST when exporting to the other VICH regions (Japan, North America) or countries 
following the VICH guidelines. 
Since 2008, EURL ECVAM has been working on behalf of EMA with VICH experts on the 
development of this guideline thus following up a project dating back to 1997 (more 
information is available on the EURL ECVAM website; AGAATI, 2002).  
The work on a comparable VICH guideline for live veterinary vaccines started in 2013 with 
EURL ECVAM as topic leader.  
5.3 EURL ECVAM support to ECHA 
During 2013, EURL ECVAM carried out a project for the European Chemicals Agency (ECHA) 
under the terms of a Service Level Agreement (SLA/ECHA-JRC/2012-2).  The aim of the 
project was to develop a reference report on the state of the science of non-standard 
methods that are available for assessing the toxicological and ecotoxicological properties 
of chemicals. Non-standard methods refer to alternatives to animal experiments, such as 
in vitro tests and computational models, as well as animal methods that are not covered 
by current regulatory guidelines. 
ECHA needs to have up-to-date information on non-standard methods since the Agency is 
responsible for implementing different regulatory processes in which there is an obligation 
or an opportunity to use non-standard methods, depending on the context. These processes 
relate to the REACH regulation, the Biocidal Products Regulation (BPR), as well as the 
Classification and Labelling and Packaging (CLP) Regulation. 
To support ECHA in examining cases where non-standard data are used or proposed under 
the above-mentioned regulations, the reference report covers the current scientific status, 
with commentary on the mechanistic basis and regulatory applicability, of methods for a 
range of human health and ecotoxicological endpoints. In particular, the following human 
health endpoints are covered: a) skin irritation and corrosion; b) serious eye damage and 
eye irritation; c) skin sensitisation; d) acute systemic toxicity; e) repeat dose toxicity; f) 
genotoxicity and mutagenicity; g) carcinogenicity; h) reproductive toxicity (including effects 
on development and fertility); i) endocrine disruption relevant to human health; and j) 
toxicokinetics. In relation to ecotoxicological endpoints, the reference report focuses on 
non-standard methods for acute and chronic fish toxicity.  
The reference report will be published as a JRC Science and Policy report during 2014. 
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5.4 European Partnership for Alternative Approaches to Animal Testing 
(EPAA) 
5.4.1 EPAA Carcinogenicity Workshop 
To compare regulatory requirements in different sectors and to look for opportunities for 
cross-sector learning that could lead to appreciable 3Rs benefits, a questionnaire was 
designed and sent to The European Partnership for Alternative Approaches to Animal 
Testing (EPAA) partners, involved in human medicine (European Federation of 
Pharmaceutical Industries and Associations (EFPIA)), veterinary medicine (International 
Federation for Animal Health Europe (IFAH-Europe)) and crop protection (European Crop 
Protection Association (ECPA)). Based on the outcome of this survey, it became evident that 
especially in the field of carcinogenicity, different schemes operating in the European Union 
regulate different types of chemical products. A conference was held in Brussels in 2013 
where representatives of the pharmaceutical, animal health, chemical and crop protection 
industries, together with representatives of other stakeholders, met under the auspices of 
the EPAA to discuss the varying requirements for carcinogenicity testing, and how these 
studies might be refined to improve hazard evaluation and risk assessment while 
implementing principles of the 3Rs. Whilst there are some similarities, the regulatory 
approaches in all four sectors have varying degrees of flexibility in requirements for 
carcinogenicity testing, to an extent reflecting concerns over the magnitude and duration of 
human exposure, either directly as in therapeutic exposure to pharmaceuticals, or indirectly 
through the ingestion of residues of veterinary drugs or crop protection chemicals (Annys 
et al., 2014). It was also recognised that there is significant scope for the harmonisation of 
testing requirements while extending the interests of the 3Rs in terms of replacement, 
refinement and reduction in the design and conduct of carcinogenicity studies. It was 
recommended that consideration of alternative methodologies should be data-driven, and 
should involve industry and regulators from the sector involved.  
5.4.2 EPAA Platform on Regulation 
5.4.2.1 EPAA Project on "Harmonisation on Biologicals" 
The project aims at progressing harmonisation of requirements for batch testing of 
vaccines and other biological products at global level. Due to evident differences in the 
current regional requirements, manufacturers may need to carry out animal tests which 
are no longer required in Europe, if they want to market their products outside of Europe.  
In a first step, regulatory bodies, key requirements and differences in the various regions 
are mapped and possible areas for harmonisation defined. It is planned to organise a 
workshop and discuss the findings and possible ways forward with regulatory bodies in 
late 2014. EURL ECVAM is a member of the project team. More information is available on 
the EPAA website10. 
                                              
10
 http://ec.europa.eu/enterprise/epaa/platform-regulation/biologicals/biologicals-project_en.htm 
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5.4.2.2 EPAA Project on "The Vaccines Consistency Approach" 
In order to facilitate the introduction of the consistency approach for the quality control of 
established human and veterinary vaccines, EPAA has initiated a project aiming at 
developing and validating non-animal methods with the support of stakeholders from 
academia, regulators, Official Medicines Control Laboratories (OMCLs), European 
Directorate for the Quality of Medicines & HealthCare (EDQM), European Commission and 
vaccine manufacturers. The project's Technical Committee agreed on four priority 
vaccines/vaccine groups (diphtheria/tetanus/acellular pertussis vaccines; human rabies 
vaccines; veterinary rabies vaccines; clostridial vaccines) and established expert working 
groups to explore ways to implement the consistency approach. For this purpose, 
workshops were organised during 2012 and 201311.  Two collaborative studies have been 
launched in 2013 and will be finalised in 2014. The clostridial vaccines group is validating 
cell culture based methods to replace the Minimum Lethal Dose and Total Combining 
Power assays required for in-process control of Clostridium septicum vaccines. The 
experimental work started early in 2014 and a workshop will be held later in the year to 
discuss the results. The human rabies vaccines group aims at replacing the current in vivo 
method for potency testing of rabies vaccines with an in vitro antigen quantification assay. 
Since several methods are in use, the group launched a study for selecting the most 
suitable ELISA for quantitation of glycoprotein-G, involving reagents (vaccines and 
standards) from three manufacturers and testing in five laboratories. The European 
Commission (via EURL ECVAM) is providing funding for carrying out independent statistical 
data analysis. EPAA will host a meeting later in 2014 to discuss the findings and make 
recommendations for a formal collaborative study to the Biological Standardisation 
Programme of EDQM. The meeting will be shared with the veterinary rabies group. 
5.5 Development of Integrated Approaches to Testing and Assessment 
5.5.1 Guidance Document on IATA on skin sensitisation 
In order to replace animal testing for the assessment of skin sensitisation, it is proposed 
that a combination of alternative methods addressing key mechanisms of the skin 
sensitisation pathway will be needed. Efforts are underway to develop integrated 
approaches for predicting skin sensitisation potential and potency based on the use of 
various information including predictions from in silico, in chemico, and in vitro methods. 
Following an initial proposal for integrating information from alternative methods by 
Jowsey et al. (2006), a number of different approaches for data integration have emerged 
since then, most of which foresee the use of data generated with the validated test 
methods mentioned above.  These integration approaches range from more simple 
sequential testing strategies (van der Veen et al., 2014; Nukada et al., 2013) and 
statistical/weight-of-evidence based solutions (e.g. Natsch et al., 2009; Bauch et al., 2012,) 
to Bayesian Networks which encode probabilistic relationships among the input variables 
                                              
11
 see flash reports on the project website http://ec.europa.eu/enterprise/epaa/platform-
regulation/vaccines/vaccines-consistency_en.htm 
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(Jaworska et al., 2013) and artificial neural network analysis of data from multiple in vitro 
assays (Tsujita-Inoue et al., 2014). In addition, the use of mathematical models is being 
explored to quantify the relationship between the dose of sensitiser applied to the skin and 
the extent of the hapten-specific T cell response that would result in humans (Maxwell et 
al., 2014).  
As described in its strategy paper (EC EURL ECVAM, 2013b), EURL ECVAM is contributing to 
the development of non-animal integrated approaches, underpinned by physico-chemical 
properties, in silico predictions and data from mechanistically relevant in chemico and in 
vitro methods. Such approaches are envisaged to have the capability not only to 
discriminate between sensitisers and non-sensitisers but also to categorise sensitisers into 
sub-categories 1A and 1B of UN GHS (UN GHS; UN 2013). EURL ECVAM is collaborating 
with ECHA in making sure that the developed approaches will fulfil information 
requirements under the 2018 REACH registration deadline. 
A complementary project is pursued by the Cosmetics Europe Skin Tolerance Task Force 
consisting of a multiple-phases evaluation program for prioritising test methods for 
assessing their contribution within integrated approaches, with the ultimate goal to deliver 
non-animal testing strategies for potency prediction. The US National Toxicology Program 
Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) is 
evaluating high-throughput screening assays for skin sensitisation in coordination with the 
US National Institute of Environmental Health Sciences (NIEHS) Tox21activities. In addition, 
the US Interagency Coordinating Committee on the Validation of Alternative Methods 
(ICCVAM) recently communicated their intention to start activities aimed at designing 
integrated decision strategies based on the use of data from EURL ECVAM validated 
methods (DPRA, KeratinoSens™ and h-CLAT)  and in silico predictions. In the light of the 
above it is foreseen that different integrated approaches for skin sensitisation that will 
cover different regulatory goals (i.e. hazard identification and/or potency prediction) will 
become available in the near future. It will be therefore important to have a consistent 
approach for their assessment and application. To this end EURL ECVAM is playing a 
prominent role at the OECD in the definition of guidance on how to document and evaluate 
IATA in view of their intended applications in order to promote their international 
acceptance. This project foresees the development of a general framework for skin 
sensitisation IATA suitable for all chemicals and regulatory applications. Different 
integrated approaches, targeting various regulatory needs, will be described in a consistent 
manner to help identifying strengths and limitations of each ultimately to facilitate 
interpretation of predictions by end-users.  
5.5.2 Guidance Document on IATA on skin irritation/corrosion 
In the past two years, EURL ECVAM has been involved, through participation in the OECD 
expert group on skin corrosion/irritation, in the development and drafting of a Guidance 
Document (GD) on an Integrated Assessment and Testing Approach (IATA) for skin 
corrosion and irritation testing, a project led by Germany. The impartiality of JRC scientists, 
acknowledged by all participants of the OECD expert groupwhich contains also 
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stakeholders with vested interests, helped in resolving some contentious issues and 
allowed finalising the GD so that it could be adopted by the WNT in 2014. 
 
Briefly, the GD builds on the Integrated Testing Strategy developed for REACH in 
2006/2007 under ECVAM coordination, but provides, as its major innovation, a more 
systematic approach towards the performance characterisation of individual information 
sources. The IATA is composed of well described and characterised “Modules” (i.e. distinct 
information sources such as testing and non-testing methods). The strengths and 
limitations as well as the potential role and contribution of each Module and their 
individual components in the IATA for skin irritation and corrosion are described with the 
purpose of minimizing the use of animals to the extent possible. Furthermore, the IATA 
includes, in line with provisions of the REACH Regulation (e.g. Annex XI) already 
implemented in 2007, reference to test methods that have not (yet) been validated and 
are not (yet) internationally recognized. Moreover, the GD's guidance on how to integrate 
the information from various sources exploits recent activities (e.g. subcategorisation by 
RhE-based assays for skin corrosion) and experiences and is more prescriptive than the 
current ITS related to REACH (ECHA, 2013). 
 
The rationale for developing the GD was as follows: Since 2002, the OECD TG 404 on in 
vivo acute dermal irritation and corrosion testing (OECD, 2002) contains a supplement 
describing a sequential testing and evaluation strategy for skin corrosion and irritation. 
While this supplement is not covered by the OECD Council decision on Mutual Acceptance 
of Data (MAD), it has nevertheless provided valuable guidance on how to consider existing 
information and organise the generation of new testing data on skin corrosion/irritation. 
Steps 5 and 6 of this sequential testing and evaluation strategy refer to validated and 
accepted in vitro or ex vivo test methods for skin corrosion and skin irritation, respectively, 
before the use of the in vivo test (i.e. TG 404) in step 7. This was intended to minimise 
animal use. However there was some ambiguity within this strategy as it does not foresee 
the use of negative results from validated and accepted in vitro skin irritation assays, 
which can be understood as requiring confirmatory in vivo testing in such situations. Since 
publication of the supplement in 2002, several Test Guidelines on in vitro methods for skin 
corrosion or irritation have been published and/or updated, notably TG 439 (OECD, 2013, 
first released in 2010) on in vitro skin irritation and TGs 430 (OECD 2013b), 431 (OECD, 
2013c) and 435 (OECD, 2006) on in vitro skin corrosion. Depending on country 
requirements, the now available validated and OECD accepted in vitro methods may satisfy 
all information requirements for skin corrosion and irritation. In addition, test methods not 
yet covered by regulatory guidelines at national, supranational or international level may 
provide further information required by some authorities, e.g. on sub-categorisation of 
corrosives or information on Category 3 irritants. Although the suitability of such data for 
regulatory purposes needs to be judged case-by-case, they should be considered before 
conducting animal tests. Thus, the supplement to TG 404 required update in view of 
amending the possible use and usefulness of individual test methods described within this 
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strategy and in order to avoid contradiction between the provisions of individual TGs on in 
vitro methods and the provisions of the TG 404 supplement. Moreover, in view of growing 
experience with the composition and use of IATAs, in particular for this specific health 
endpoint, a revision in view of incorporating current scientific and regulatory considerations 
and practices seemed timely.  
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6. Dissemination of Information and Alternatives12 
6.1 In vitro methods 
6.1.1 DB-ALM—EURL ECVAM’s DataBase service on ALternative Methods to 
animal experimentation  
The readily access to comprehensively described methods is a prerequisite for their use 
within decision making processes by regulators and scientists or any end-user in 
biomedical sciences and toxicology. The DB-ALM13 provides standardised descriptions of 
methods that are at all stages of development, validation or regulatory acceptance in the 
different policy areas and for different purposes. Information at various level of detail is 
provided and defined according to pre-determined criteria for data content by experts in 
the field. Current focus is given to in vitro methods used for safety assessments of 
chemicals and/or formulations, but it is not limited to it.   
The method reporting formats have evolved to the state-of-the-art of science and 
costumer needs so as to capture all information elements necessary to allow judgments of 
its usefulness, that now cover: information on the potential of a method including its 
intended objectives and applications, the scientific principle and  need for it, a summary 
description of study results obtained so far including performance and reliability 
evaluations as available and appropriate, discussions on strengths and eventual limitations 
completed with their status of development, validation or regulatory acceptance.  
Status  
 Contents 
To date the DB-ALM provides the following information: 
Information Sector Data Sheet Number 
Topic Summaries 5 
Method Summaries 157 
Protocols 147 
Evaluations, EU projects, Validation studies 85 
Test Results (individual investigations) 9231 
Persons & Institutions active in the field of 
alternative methods 
238 
Bibliographic References 7003 
                                              
12
 The EURL ECVAM databases on alternative methods originate from the Communication of the Commission 
to Council and European Parliament SEC(91)1794, further reinforced by Directive 2010/63. 
13
 DB-ALM: http://ecvam-dbalm.jrc.ec.europa.eu 
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During 2013 the online information content has been enhanced with particular focus on 
methods submitted for validation and those originating form EU Integrated Projects, such 
as ACuteTox. In total 17 methods in the form of summary descriptions or protocols and 
related information have been revised or newly published; further 14 are close to 
finalisation.  In total, 5 topic areas in the form of thematic reviews are covered providing 
method summary descriptions and related information, while individual protocols are made 
available for 25 topic areas addressing human health and ecotoxicological effects of 
chemical substances, mechanistic information, quality control of biological products, and 
biocompatibility and safety testing of medical devices.  
Over 150 biological endpoints are moreover addressed referring to biological processes, 
responses or effects that can be measured at various levels of biological organisation, 
such as: 
 interactions on the molecular level (including biochemistry and bio-kinetics) 
 basal cytotoxicity testing  
 functional parameters of organs and tissues 
 model organism responses 
The methods can be consulted at the address provided.  
 Usage  
The year 2013 has seen a duplication in the number of new registrations compared to the 
same period of the year before and a download of medially 300 documents/months 
representing an increase by 65 % compared to the same period of 2012.  In total, the DB-
ALM can refer to over 3500 registered users from 82 countries covering representatives 
from academia (45%), industry (33%) and regulators (13%), the animal welfare movement 
and others (9%).  
Further in 2013, the OECD Advisory Group on Molecular Screening and Toxicogenomics has 
set up a drafting group to develop guidance for characterising non-guideline in vitro 
methods used for regulatory purposes as a supplement to the existing guidance for 
development and assessment of Adverse Outcome Pathways. The DB-ALM was considered 
as a potential public resource for storing those methods in a standardised manner. 
6.1.2 TSAR (Tracking System for Alternative test methods towards Regulatory 
acceptance) 
A first version of TSAR14 has been set up by the Joint Research Centre to track progress, in 
a transparent manner, from proposal of an alternative method for validation through to its 
final adoption by its inclusion into the regulatory framework (EU, OECD and related 
standards). An entirely revised version will be made available by the end of 2014. It will 
also address the needs of the individual partners participating in the International 
                                              
14
 TSAR: http://tsar.jrc.ec.europa.eu/index.php?process=1&stage=1 
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Collaboration on Alternative Testing Methods (ICATM) providing in this way an overall view 
of the methods under evaluation by all ICATM partners from one public access point. 
6.2 In silico methods 
JRC QSAR Model Database 
The JRC QSAR Model Database15 is a freely accessible web application that enables users 
to submit, publish, and search QSAR Model Reporting Format (QMRF) reports. Developers 
and users of QSAR models can submit to the dedicated mailbox information on QSARs by 
using the QMRF. A downloadable QMRF editor is used for this purpose. The JRC then 
performs a quality control (i.e. adequacy and completeness of the documentation) of the 
QMRF submitted. Properly documented QMRFs are included in the JRC QSAR Model 
Database. Inclusion of the model does not imply acceptance or endorsement by the JRC or 
the European Commission, and responsibility for use of the models lies with the end-users.  
Status of QMRFs in the JRC QSAR Model Database 
At the time of writing (March 2014), the JRC QSAR Model Database contains 70 QMRFs, 
including two for physical chemical properties, 12 for environmental fate parameters, 23 
for ecotoxic effects, 30 for human health effects, two for toxicokinetic properties and one 
for chromosome damage. A number of additional QMRFs will also be uploaded in a new 
version of the database that will be launched in 2014 from the same webpage. 
 
                                              
15
 http://qsardb.jrc.ec.europa.eu/qmrf/ 
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 To date the QSAR database provides the following information content: 
Figure 2. Information content provided by the QSAR database 
6.3 Information Retrieval Guidance 
EURL ECVAM Search Guide 
After the success that the EURL ECVAM Search Guide16 reached in 2012, the JRC has 
decided to re-publish an entirely updated version which is available as a printed version 
(handbook) or as an E-Book from the EU Bookshop since August 2013. It is continuing to be 
used as a resource for higher education in academic institutions and by national authorities 
for project authorisations. 
The Guide has specifically been developed to inform and support untrained database users 
to find high quality information on relevant alternative methods and strategies in the large 
amount of available information resources as an easy, yet systematic, and efficient way.  
 
  
                                              
16
 The Guide: http://bookshop.europa.eu/en/the-eurl-ecvam-search-guide-pbLBN124391 
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7. International Cooperation on Alternative Methods (ICATM) 
7.1 Context of ICATM Establishment  
The International Cooperation on Alternative Methods was formally established on April 
27th, 2009 through the signature of a Memorandum of Cooperation (MoC). Through this 
MoC, ICATM partners recognized that their purpose is to promote consistent and enhanced 
voluntary international cooperation, collaboration, and communication among national 
validation organizations. This purpose may be achieved through five objectives:  
1. further the optimal design and conduct of validation studies to support national and 
international regulatory decisions on the usefulness and limitations of alternative 
methods;  
2. further high quality independent scientific peer reviews of alternative test methods 
that incorporate transparency and the opportunity for stakeholder involvement;  
3. enhance the likelihood of harmonized recommendations by validation organizations 
on the usefulness and limitations of alternative test methods for regulatory testing 
purposes;  
4. achieve greater efficiency and effectiveness by avoiding duplication of effort and 
leveraging limited resources;  
5. support the timely international adoption of alternative methods.  
 
Four organizations originally signed this MoC on April 27th, 2009:  
1. the Japanese Center for the Validation of Alternative Methods (JaCVAM), within the 
National Institute of Health Sciences;  
2. the US National Toxicology Program (NTP) Interagency Center for the Evaluation of 
Alternative Toxicological Methods (NICEATM), a component of the National Institute 
of Environmental Health Sciences, administers the U.S. Interagency Coordinating 
Committee on the Validation of Alternative Methods (ICCVAM);  
3. the European Centre for the Validation of Alternative Methods (ECVAM), within the 
Institute for Health and Consumer Protection, Joint Research Centre, European 
Commission;  
4. the Environmental Health Science and Research Bureau within Health Canada. 
 
On March 8th, 2011 a fifth partner organization, the Korean Center for the Validation of 
Alternative Methods joined the ICATM and an updated MoC was signed by all partners for 
this purpose. 
 
Since the establishment of ICATM, all partners met several times a year in order to 
reinforce their cooperation, address further the terms and practicalities of this 
collaboration and present updates on their activities. 
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Annex II presents a table summarizing ICATM activities on alternative test methods 
validation and regulatory acceptance. 
7.2 ICATM Meetings in 2013 
In 2013, the ICATM partners met three times, in Tokyo (Japan) on February 12th, 2013; in 
Seoul (Korea) on July 3rd, 2013 and in Ispra Joint Research Centre (Italy) on November 26-
27th, 2013. ICATM partners received a letter of interest from the Brazilian Center for 
Validation of Alternative Methods (BraCVAM) on May 31st, 2013 to join ICATM.  
 
During these meetings ICATM partners presented updates of their respective activities, 
progresses achieved towards the validation of alternative methods, and presented their in 
house specific procedures. In that respect, they re-evaluated the scope of the MoC and 
agreed that it was describing correctly, and within a broad extent, their collaboration. They 
recognized that ICATM collaboration practices would ideally be agreed upon in consensus. 
In these meetings, the partners addressed five main areas of cooperation for the validation 
of alternative methods that are:  
 
1. Conduct of validation studies; 
2. Conduct of peer reviews; 
3. Harmonized approaches; 
4. Communication and dissemination; 
5. Strategic considerations with regard to international regulatory acceptance. 
7.3 ICATM Achievements in 2013 
At their latest meeting in November 2013, ICATM partners discussed their activities and set 
up a more sustainable cooperation. During this two-days meeting they widely exchanged 
information on their mandates, objectives, priorities, functioning, and interaction with other 
parties—such as e.g. national/international regulators and stakeholders. They addressed 
further opportunities for cooperation with regard to a broad range of topics related to 
alternative methods.  
 Regarding the selection and prioritisation of test methods, ICATM partners agreed 
on key criteria to be met: regulatory relevance, impact on the 3Rs and on human 
health & environmental protection; scientific value; scientific and regulatory gaps 
addressed and costs involved. 
 Regarding the conduct of validation studies, ICATM partners agreed to strengthen 
their collaboration on a voluntary basis and to create guidance on how validation 
studies should be conducted. They examined technical aspects encountered in 
validation studies of in vitro methods especially for the chemicals selection; the 
establishment of validation management groups (VMGs); the selection of 
participating laboratories; the potential harmonisation of study designs. They also 
discussed thoroughly the expertise that needed to be covered by Validation 
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Management Group (VMG) members as well as their respective contribution to and 
involvement in the VMGs of the other ICATM partners. 
 Regarding the conduct of peer-reviews, ICATM partners converged in their views. 
They agreed that peer reviews should be independent—i.e. carried out by persons 
without any vested interest in the evaluated test method/approach—and performed 
through a scientific approach that thoroughly evaluates quality of studies and their 
results. The peer review process should deliver opinions and recommendations on 
the scientific validity of a test method. ICATM partners recognized the interest of 
sharing peer review outputs and getting mutually informed about their 
recommendations. After the conduct of a peer review, the ICATM partner to whom a 
method has been submitted will then communicate a position to regulators and 
relevant stakeholders, which will serve as a basis for regulatory acceptance at the 
international level. ICATM decided to further compare peer review processes in 
which they are involved in order to extend their future collaboration and enable 
reciprocally reference to each other peer reviews. 
 For the communication and dissemination, they agreed to facilitate communication 
amongst themselves and towards regulators and stakeholders. ICATM partners aim 
to promote transparency and disseminating information to the public on alternative 
test methods that are being evaluated for regulatory purposes. For this purpose, 
they agreed to use the EURL ECVAM Tracking System for Alternative methods 
towards Regulatory acceptance (TSAR) currently under development, and analysed 
implications of potential dissemination through this common platform. 
 They decided that their cooperative activities should encompass both validation and 
research/development with a regulatory objective. They also agreed to work 
together on topical toxicity, skin sensitisation, endocrine disruptors, biokinetics and 
genotoxicity.  
 ICATM partners widely addressed opportunities for cooperation with regards to their 
involvement in international programmes, and concurred to develop sustained 
activities. They decided to expand their upstream collaboration on activities 
regarding the Organisation for Economic Cooperation and Development (OECD), and 
to support each other at the level of the International Conference on Harmonisation 
of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 
and any other international programmes, when relevant. This includes getting 
reciprocally informed whenever possible on submission of projects in order to 
efficiently cooperate on test methods and approaches addressing the 3Rs and on 
their regulatory acceptance and impact.  
7.4 ICATM involvement in Validation Management Teams (VMTs). 
In 2013, EURL ECVAM was involved in ICATM collaborations as liaisons in validation 
management teams in the areas of eye irritation and reproductive and developmental 
toxicity. Currently, EURL ECVAM activities in VMTs include the cooperation in three different 
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validation studies led by JaCVAM i.e., the Hand1-Luc Stem cell test, the SIRC CVS and the 
Vitrigel-EIT.  
 
The Hand1-Luc stem cell based test, designed to evaluate developmental toxicity of 
chemicals is undergoing a JaCVAM coordinated validation study. Currently, between-
laboratory reproducibility and predictive capacity of the test method are assessed. 
Another JaCVAM coordinated validation study is currently conducted with the SIRC-CVS 
cytotoxicity test assay in the area of eye irritation. The SIRC-CVS assay is related to the 
Short term exposure (STE) test, that is currently under review at the OECD. The SIRC-CVS 
assay is intended to be used in an initial step of a bottom-up approach for eye irritation 
testing. Currently the predictive capacity  of the test method using blinded test chemicals is  
evaluated. 
 
The Vitrigel-Eye Irritancy Test (EIT) method is based on a human corneal epithelial cell line, 
grown on a scaffold of a collagen vitrigel membrane, containing high-density collagen 
fibrils equivalent to connective tissue as a three-dimensional cell culture model. Changes in 
the transepithelial electrical resistance (TEER) in response to the exposure of a test 
chemical, using the barrier function of the epithelium as an indicator allows the estimation 
of its irritancy potential. In an initial study, 30 Chemicals were tested for their correlation 
between the GHS classification and Vitrigel EIT. Data from this study suggests that eye 
irritation potential can be determined by this test method with a very low false negative 
rate. A JaCVAM coordinated validation study according to the conceptual framework of the 
"modular approach" was launched in 2013. 
 
EURL ECVAM is also liaising with JaCVAM on the validation of the IL-8 Luc assay, a test 
method based on the use of a stable THP-1-derived IL-8 reporter cell line and proposed for 
the discrimination between sensitisers and non-sensitisers (Takahashi et a., 2011).
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8. EURL ECVAM Strategies 
8.1 EURL ECVAM strategy on how to avoid and reduce animal use for 
assessing chemicals for genotoxicity  
The EURL ECVAM strategy on how to avoid and reduce animal use for assessing chemicals 
for genotoxicity17 was published in 2013.Although several in vitro tests are available at 
different stages of development and acceptance, they cannot at present be considered to 
fully replace animal tests needed to evaluate the safety of substances. Based on an 
analysis of regulatory requirements for this endpoint within different pieces of EU 
legislation, EURL ECVAM proposes a pragmatic approach to improve the traditional 
genotoxicity testing paradigm that offers solutions in both the short- and medium-term 
and that draws on the considerable experience of 40 years of regulatory toxicology testing 
in this area. EURL ECVAM considers that efforts should be directed towards the overall 
improvement of the current testing strategy for better hazard and risk assessment 
approaches, which either avoids or minimises the use of animals, whilst satisfying 
regulatory information requirements, irrespective of regulatory context. Several 
opportunities for the improvement of the testing strategy have been identified which aim 
to enhance the performance of the in vitro testing battery so that fewer in vivo follow-up 
tests are necessary, and guide more intelligent in vivo follow-up testing to reduce 
unnecessary use of animals. The strategy went through consultation with EURL ECVAM's 
advisory and stakeholder bodies and aims to satisfy regulatory requirements within various 
pieces of EU legislation. The implementation of this strategic plan will rely on the 
cooperation of EURL ECVAM with other existing initiatives and the coordinated contribution 
from various stakeholders. 
8.2 EURL ECVAM Genotoxicity and Carcinogenicity Database of positive 
Ames test results  
The Ames test conducted in bacteria is the most commonly used genotoxicity test within 
the in vitro battery as it is considered able to reveal DNA reactivity and DNA reactive 
compounds. It is used to assess almost all types of substances including impurities, low 
production volume chemicals, etc. Therefore, knowing whether in vitro positive results are 
accurate indicators of in vivo mutagenic potential or carcinogenicity is extremely important 
in determining whether follow-up in vivo tests are needed or whether substances should be 
further tested. Despite the many activities on false positive results in in vitro mammalian 
cell tests, positive results in the Ames test have not been analysed in the same way as for 
mammalian cell tests. In 2013 EURL ECVAM held a workshop and initiated a project with 
the aim of 1) evaluating the predictivity of the Ames for in vivo genotoxicity and 
carcinogenicity when considered alone or in association with a mammalian cell assay for 
                                              
17
 http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/30088/1/jrc_report_en_34844_online.pdf   
 
59 
 
the detection of chromosome damage and/or gene mutations, and 2) better characterising 
the cases where the Ames test seems to lead to irrelevant (false positive) results (e.g. 
chemical classes, type of bacterial strains, magnitude of effects).  As data presented at the 
workshop were from different sources (ECHA dissemination database, EFSA pesticides, 
carcinogens of the Carcinogenicity and Genotoxicity eXperience database (CGX), US NTP, US 
FDA, NTP, FDA, Japanese CSCL and ISHL, SCCS and other industry databases), and some of 
the chemicals were duplicated across different databases, EURL ECVAM constructed a 
consolidated database (manuscript in preparation) that will represent a powerful resource 
for data analysis and can be used to guide a thorough evaluation of genotoxicity and 
carcinogenicity. 
8.3 EURL ECVAM Strategy to avoid, reduce and refine the use of animals 
in the assessment of acute systemic toxicity 
The EURL ECVAM strategy is based on the assessment of the regulatory needs for acute 
systemic toxicity and the current state of the science in the area of acute systemic toxicity, 
including recent and ongoing efforts.  Currently, only in vivo tests are accepted by 
regulatory bodies and most of them use lethality as an apical endpoint. One of the main 
drivers for conducting these standard tests is classification and labelling of substances. 
The development of mechanistically-based alternative methods and strategies for acute 
systemic toxicity is desirable; however it is still hampered by the limited understanding of 
the key acute toxicity pathways in humans.  Although to date, in vitro cytotoxicity assays 
are recognised only as additional tests that can be used for estimating the initial doses for 
acute oral systemic toxicity tests in vivo (OECD GD N°129), the evidence indicates that the 
3T3 NRU basal cytotoxicity assay can be used to support the identification of negatives 
(non-classified substances – i.e. oral LD50 value > 2000 mg/kg b.w.), with the caveat that, 
due to the limitations of this test method, results should always be used in combination 
with other information sources to build confidence in the decision not to classify a 
substance for acute oral toxicity (EC ECVAM, 2013). With this in mind, EURL ECVAM 
proposes to explore options to make better use of existing alternative methods, such as the 
validated 3T3 NRU cytotoxicity assay, since the information provided is expected to 
contribute to the weight-of-evidence in future IATA for acute systemic toxicity. Information 
on repeat dose toxicity, if available, might also be informative and useful to support 
classification and labelling. Special consideration should be given to collecting and 
organising mechanistic knowledge of acute systemic toxicity in order to improve the design 
and validation of integrated prediction models. In addition, EURL ECVAM will continue to 
support activities aimed at the refinement of relevant in vivo studies. The strategy is now 
under consultation with EURL ECVAM's advisory and stakeholder bodies. After its 
publication, the implementation will rely on the cooperation of EURL ECVAM with other 
related initiatives and the contribution from various stakeholders.  
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8.4 EURL ECVAM Strategy to avoid, reduce and refine the use of fish in 
aquatic toxicity and bioconcentration/bioaccumulation testing 
EURL ECVAM is currently drafting its strategic plan on activities that are expected to have a 
3Rs impact in the area of aquatic toxicity and bioaccumulation. It is based on an 
assessment of the regulatory needs for these endpoints and on the scientific state-of-the 
art in the areas, including recent and ongoing activities. The strategy will also provide a 
framework for the prioritisation of alternative test methods submitted to EURL ECVAM for 
validation. 
8.5 Update on the EURL ECVAM Strategy on Toxicokinetics 
At the time of writing, a draft for the EURL ECVAM Strategy on Toxicokinetics (TK) was 
under preparation. In order to improve risk assessment methodology for human health 
related to exposure to chemicals and create a basis to address some prominent public 
health issues in this field, The Toxicokinetics Strategy document has as a single 
overarching aim to strive for a transition from the traditional approach based on external 
exposure dose metrics to an approach based on internal dose metrics. . An important topic 
is the necessity to develop standards necessary to characterise in vitro and in silico 
methods that measure individual ADME parameters. In vitro methods standards will be 
instrumental to determine the performance of an in vitro ADME method. Developing a 
series of in vitro ADME methods with an acceptable level of performance (relevance and 
reliability) and a toolbox of standards (standard methods) to measure that performance 
for each method in relation to its use case seems to become a challenging need. 
Furthermore, good physiologically-based toxicokinetic (PBTK) modelling practices will be 
necessary to facilitate the use of PBTK modelling in a risk assessment environment. As 
such the issuing of guidance on the development and use of toxicokinetic data in testing 
and assessment strategies using case studies approaches will be an action that will be 
necessary. In summary, five key topics are defined: standards for in vitro and in silico 
ADME methods, GMP for good PBTK modelling practices, databases for ADME parameters, 
databases for measured TK data and guidance for the use of ADME and TK in IATA. 
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9. Conclusion 
EURL ECVAM’s activities in 2013 to April 2014 covered a broad range of topics, from R&D 
in areas still lacking 3Rs solutions (e.g. repeated dose toxicity testing) to leading efforts 
towards the international adoption of Test Guidelines and Guidance Documents in areas 
which are more advanced (e.g. skin irritation/corrosion, eye irritation and skin sensitisation). 
Research and development activities undertaken to tackle the complex endpoints have 
yielded a wide variety of new methodologies and tools for mechanistic-based toxicology, 
such as complex bioreactors for engineering of human tissues, innovative 'omics' technics, 
differentiation protocols for human induced pluripotent stem cells and computational 
modelling tools. It is currently being assessed how this range of complementary non-
animal methods can be integrated according to a toxicological MoA/AOP framework. 
EURL ECVAM strategy papers were developed in the areas of genotoxicity, acute systemic 
toxicity, aquatic toxicicity and bioconcentration/bioaccumulation testing and toxicokinetics. 
These strategies address different regulatory areas  (e.g. chemicals, cosmetics, biocidal 
products, pharmaceuticals) and their related needs. They review the progress made so far, 
identify gaps and opportunities in relation to method development and validation and 
outline what actions should be taken to deliver solutions with 3Rs impact. They are 
developed in close consultation with EURL ECVAM's network of regulators, stakeholders 
and international partners.  
The Adverse Outcome Pathways framework, guiding the design of Integrated Approaches 
to Assessment and Testing (IATA), provides a knowledge-based safety assessment 
framework that enables the selection of the most relevant test methods for validation. The 
availability of a toolbox of validated alternative methods addressing key events of an AOP 
and incorporated in IATAs facilitates the regulatory acceptance/adoption process of 
alternative methods at both international and European level and their global use. It is 
anticipated therefore that as various AOP-related initiatives gain momentum in the years 
ahead, more clarity and opportunity will emerge on where to target efforts in the 
development and validation of alternative methods to maximum effect.    
International cooperation between multiple entities active in the3Rs is an essential element 
to progress the field. EURL ECVAM continues therefore to engage proactively on an 
international stage endeavouring to guide the integration of efforts and to provide 
leadership in key areas where it has competence. 
In conclusion, considerable progress has been made in many aspects of the development, 
validation and regulatory acceptance of alternative methods and approaches during the 
period March 2013 to April 2014. This rate of progress can be maintained with continuing 
commitment from the 3Rs community coupled with sustained investment and support 
from a variety of key actors and stakeholders.     
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Annex I—Summary status of the adoption of Test Guidelines based on alternative methods in the OECD 
TG programme (2012-2014) 
Table 1 summarises the status of adoption of OECD test guidelines on alternative methods from 2012 to 2014. It should be noted that 
beside TGs, also Guidance Documents and new projects on alternative methods were respectively adopted and included on the OECD Work 
programme during that period. For additional information, please consult the OECD website of the Test Guideline Programme: 
http://www.oecd.org/env/ehs/testing/oecdguidelinesforthetestingofchemicalsandrelateddocuments.htm 
 
Table 1.  Status of adoption of OECD Test Guidelines based on alternative methods 2012-2014 
Nr. Toxicity area Test method description Acceptance status 
1 Skin corrosion Reconstructed human Epidermis test methods 
(RhE) as included in OECD TG 431/EU TM B.40 bis 
Adopted in 2004; updated version (sub-
categorisation, inclusion of performance 
standards, inclusion of SkinEthic™ RHE 
and epiCS®) adopted in 2013. Revised 
version including sub-categorisation with 
the epiCS® test method adopted in 2014 
2  Transcutaneous Electrical Resistance (TER)  test 
as included in OECD TG 430/EU TM B.40 
 
Adopted in 2004; updated version 
(inclusion of performance standards) 
adopted in 2013 
3 Skin irritation Reconstructed human Epidermis test methods 
(RhE) as included in OECD TG 439/EU B.46 
Adopted in 2010; updated version 
(inclusion of LabCyte EPI-model24 SIT) 
adopted in 2013 
4 Serious eye damage/eye 
irritation  
Fluorescein Leakage (FL) test method as included 
in OECD TG 460 
Adopted in 2012 
5  Bovine Corneal Opacity and Permeability (BCOP) 
test method as included in OECD TG 437/EU TM 
B.47 
Adopted in 2009; updated version 
(revision of positive controls, use to 
identify non-classified chemicals) 
adopted in 2013 
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Nr. Toxicity area Test method description Acceptance status 
6  Isolated Chicken Eye (ICE) test method as 
included in OECD TG 438/EU TM B.48 
Adopted in 2009, updated version (use to 
identify non-classified chemicals) 
adopted in 2013 
7  Cytosensor Microphysiometer (CM) test method New draft TG discussed at WNT in 2013 
but not yet adopted, pending further 
clarification on its use to identify non-
classified chemicals 
8  Short Time Exposure (STE) test Draft TG underwent one commenting 
round in November 2013 and will 
undergo a second commenting round in 
view to be considered for adoption in 
April 2015 
9 Skin sensitisation Direct Peptide Reactivity Assay (DPRA) New draft TG underwent one 
commenting round in November 2013 
Revised TG circulated to the WNT in May 
2014 for review and approval by written 
procedure 
10  KeratinoSens New draft TG underwent one 
commenting round in November 2013 
Revised TG circulated to the WNT in May 
2014 for review and approval by written 
procedure 
11 Carcinogenicity Cell Transformation Assay (CTA) SHE  New draft TG discussed at WNT in 2013 
but not yet adopted. Draft TG was not 
adopted by WNT  in 2014 either, but will 
be considered for adoption as Guidance 
Document after revisions 
12  Cell Transformation Assay (CTA) Bhas 42 New draft TG underwent one 
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Nr. Toxicity area Test method description Acceptance status 
commenting round. Draft TG will undergo 
a second commenting round in view to 
be considered for adoption in April 2015 
 
13 Genotoxicity Existing OECD TGs under revision Revised OECD TG 473 (in vitro 
chromosome aberration assay; originally 
adopted in 1997) and OECD TG 487 (in 
vitro mammalian cell micronucleus test; 
originally adopted in 2010) adopted in 
2014 
14 Endocrine disruption Estrogen receptor transactivation assay (BG1Luc 
ER TA; agonist and antagonist protocols) as 
included in OECD TG 457 
Adopted in 2012 
15  Performance-Based Test Guideline for Stably 
Transfected Transactivation In Vitro Assays to 
Detect Estrogen Receptor Agonists OECD TG 455 
Adopted in 2009 (STTA assay using the 
hERα-HeLa-9903 cell line); updated 
version (PBTG, inclusion of BG1Luc ER TA 
assay using the BG1Luc-4E2 cell line) 
adopted in 2012 
16 Acute  fish toxicity  Fish Embryo Acute Toxicity (FET) Test as included 
in OECD TG 236 
Adopted in 2013 
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Annex II—ICATM Alternative Test Methods Validation and Regulatory Acceptance 
Table 2. ICATM Alternative Test Methods Validation and Regulatory Acceptance 
Method Current Status Lead Action 
Organization 
International Acceptance 
Dermal Corrosivity Test Methods 
CORROSITEX Skin Corrosivity Test Completed  OECD TG 435 (2006) 
EpiSkin™, EpiDerm™, SkinEthic™, 
epiCS® Skin Corrosivity Tests 
Completed  OECD TG 431 (2004), updated 
version (sub-categorization, 
inclusion of performance 
standards, inclusion of SkinEthic™ 
RHE and epiCS™) adopted in 2013. 
Revised version including the sub-
categorization with the epiCS™ 
test method adopted in 2014 
Rat TER Skin Corrosivity Test Completed  OECD TG 430 (2004), updated 
version (inclusion of performance 
standards) adopted in 2013 
Dermal Irritation Test Methods 
In vitro reconstructed human 
epidermis (RhE) test methods: 
EpiDerm™, EpiSkin™, SkinEthic™ RHE 
and LabCyte EPI-MODEL24 SIT  
Completed 
-  
-  
 OECD TG 439 (2010),  updated 
version (inclusion of LabCyte™ 
EPI-model) adopted in 2013 
In vitro reconstructed human epidermis 
(RhE) test methods: Korean epidermis 
KoCVAM sponsored validation study 
is on-going 
KoCVAM; EURL ECVAM, 
NICEATM-ICCVAM, Health 
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Method Current Status Lead Action 
Organization 
International Acceptance 
model Canada and JaCVAM VMT 
liaisons 
Phototoxicity Test Methods 
3T3 NRU Phototoxicity Test Completed  OECD TG 432 (2004) 
Test method battery to predict 
phototoxicity (yeast growth inhibition 
phototoxicity assay and red blood cell 
photohemolysis assay) 
Japanese Regulatory Acceptance 
Board recommended additional work 
be performed 
JaCVAM  
In vitro test method based on reactive 
oxygen species (ROS) and photostability  
Peer review of the JaCVAM-
sponsored validation study finalized 
in 2013. 
 
JaCVAM; EURL ECVAM, 
NICEATM-ICCVAM, Health 
Canada and KoCVAM 
VMT liaisons 
ICH S10 including the ROS assay and 
the 3T3 NRU test method was 
completed in 2014 
Ocular Toxicity Test Methods 
Bovine Corneal Opacity and 
Permeability (BCOP) Test Method 
Completed 
 
 OECD TG 437 (2009), updated 
version (positive control, use in a 
bottom-up approach to identify 
non-classified chemicals) adopted 
in 2013 
Isolated Chicken Eye (ICE) Test 
Method 
Completed  OECD TG 438 (2009), updated 
version (use in a bottom-up 
approach to identify non-
classified chemicals) adopted at 
WNT in 2013 
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Method Current Status Lead Action 
Organization 
International Acceptance 
Use of Histopathology as an 
additional endpoint in Ocular Safety 
Testing 
Completed    OECD GD 160 (2011) 
Cytotoxicity test: SIRC CVS JaCVAM-sponsored validation study  
is ongoing 
JaCVAM; EURL ECVAM, 
NICEATM-ICCVAM, and 
Health Canada VMT 
 
Cytotoxicity test: three-dimensional 
dermal model (MATREX) 
JaCVAM-sponsored validation study 
in the planning stage 
JaCVAM; EURL ECVAM, 
NICEATM-ICCVAM, and 
Health Canada VMT 
 
Cytotoxicity test: Short Time Exposure 
(STE) test 
Peer review coordinated by NICEATM-
ICCVAM of the JaCVAM-sponsored 
validation study completed. The draft 
TG was submitted to OECD for 
comments.  
JaCVAM; EURL ECVAM, 
NICEATM-ICCVAM, and 
Health Canada VMT 
liaisons 
Draft TG underwent one commenting 
round. Draft TG will undergo a second 
commenting round in view to be 
considered for adoption in April 2015 
Use of anaesthetics, analgesics, and 
humane endpoints for routine use in 
TG 405 
 
Completed  OECD updated TG 405 (2012) 
Low volume eye test; recommendation 
for no future use.  
Completed 
-  
  
In vitro approach for categorization of 
anti-microbial cleaning products: 
recommendations for further studies 
Completed. EPA/OPP has concluded 
from submission and review of 
alternative eye irritation tests 
conducted on antimicrobial pesticide 
products with cleaning claims 
(AMCPs) that the proposed testing 
NICEATM-ICCVAM  
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Method Current Status Lead Action 
Organization 
International Acceptance 
approach is acceptable for 
determining the appropriate eye 
hazard classification and labelling for 
AMCPs (see 
http://www.epa.gov/pesticides/regulati
ng/eye-policy.pdf for the details of 
the scope of the policy). 
Cytosensor Microphysiometer® (CM) 
Test method 
The draft TG was submitted to OECD 
for comments including a set of 
Performance Standards  
EURL ECVAM; NICEATM-
ICCVAM 
New draft TG discussed at WNT in 
2013 but not yet adopted, pending 
further clarification on its use in a 
bottom-up approach 
Fluorescein Leakage (FL) test 
method 
Completed  OECD TG 460 (2012) 
Human reconstructed tissue models for 
eye irritation 
- EpiOcular™ EIT 
- SkinEthic™ HCE 
EURL ECVAM validation study 
finalized (experimental part started in 
2010 and ended in April 2013; the 
validation of an optimized 
EpiOcular™ solids protocol was 
completed in June 2013). 
Peer review of EpiOcular™ EIT 
anticipated for 2014. 
EURL ECVAM; JaCVAM, 
NICEATM-ICCVAM, and 
Health Canada VMT 
liaisons 
SPSF for EpiOcular™ EIT was approved 
by  WNT in 2014 
 
Vitrigel-EIT MAFF-sponsored validation study is 
on-going 
JaCVAM; EURL ECVAM, 
NICEATM-ICCVAM, and 
Health Canada VMT 
liaisons 
 
Immunotoxicity (Allergic Contact Dermatitis) Test Methods 
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Method Current Status Lead Action 
Organization 
International Acceptance 
Murine local lymph node assay 
(LLNA) for skin sensitization 
 
Completed  OECD TG 429 (2002) 
ISO (2002) 
Updated Murine local lymph node 
assay (LLNA) for skin sensitization 
(20% reduction) 
 
Completed  Update to TG 429 OECD (2010) 
 
ISO (2010) 
Reduced LLNA (rLLNA) 
 
Completed  Update to TG 429 OECD (2010) 
Nonradioactive LLNA protocol 
(LLNA: BrdU-ELISA) 
Completed  OECD TG 442B OECD (2010) 
Nonradioactive LLNA protocol, 
LLNA:DA 
Completed   OECD TG 442A OECD (2010) 
Harmonized performance standards 
for the LLNA 
Completed  Update to TG 429 OECD (2010) 
Nonradioactive LLNA protocol (LLNA: 
BrdU-Flow Cytometry) 
- KoCVAM validation study is on-going KoCVAM  
In vitro skin sensitization assays (h-
CLAT; DPRA; MUSST) 
Multi-laboratory validation ended in 
August 2012 (h-CLAT and MUSST). 
DPRA peer review finalized. h-CLAT 
peer review on-going..  
EURL ECVAM recommendation on 
DPRA published. 
EURL ECVAM; JaCVAM 
and NICEATM-ICCVAM 
VMT liaison members 
SPSFs for TGs on the DPRA, and hCLAT 
approved in 2012 and 2013, 
respectively. Draft TG on DPRA under 
discussion at OECD, underwent one 
commenting round. Second 
commenting round will take place in 
2014, with a view to have approval by 
WNT via written procedure in 2014 
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Method Current Status Lead Action 
Organization 
International Acceptance 
In vitro skin sensitization assay 
KeratinoSens™ 
External Validation Study, peer review 
finalized. EURL ECVAM 
recommendation published 
EURL ECVAM SPSF for a TG on the Keratinosens 
approved in 2012. Draft TG under 
discussion at OECD, underwent one 
commenting round. Second 
commenting round will take place in 
2014, with a view to have approval by 
WNT via written procedure in 2014 
In vitro skin sensitization assay 
IL-8 Luc assay 
METI-sponsored validation study is 
on-going 
 
JaCVAM; EURL ECVAM, 
NICEATM-ICCVAM, 
KoCVAM and Health 
Canada VMT liaisons 
 
Vitrigel-SST MAFF-sponsored validation study is 
on-going 
JaCVAM; EURL ECVAM, 
NICEATM-ICCVAM, and 
Health Canada VMT 
liaisons 
 
Acute Toxicity Test Methods 
Up and Down Procedure (UDP) Completed  OECD TG 425 (2008) 
In vitro cytotoxicity test methods 
for estimating starting doses for 
acute oral systemic toxicity tests 
Completed  
-  
 OECD GD 129 (2010) 
In vitro cytotoxicity test (3T3 Neutral 
Red Uptake) for identifying substances 
with acute oral LD50 > 2000 mg/kg b.w. 
 
EURL ECVAM ESAC peer review 
completed, and EURL ECVAM 
Recommendation published in 2013. 
EURL ECVAM and ICATM 
organisations 
 
Zebrafish Embryo Toxicity test (ZFET) ESAC peer review finalized. EURL 
ECVAM recommendation pending 
EURL ECVAM Adoption of OECD TG 236 in April 
2013 
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Method Current Status Lead Action 
Organization 
International Acceptance 
publication. 
Toxicokinetic test methods 
In vitro hepatic biotransformation – CYP 
induction: Hepa RG and cryopreserved 
human hepatocytes 
ESAC peer review foreseen in 2014 EURL ECVAM; NICEATM-
ICCVAM, and JaCVAM 
VMT liaisons 
SPSF for a PBTG approved  in April 
2013 
In vitro Fish Hepatic Metabolism - 
in vitro system for deriving information 
on biotransformation and improving 
reliability of bio-concentration & bio- 
accumulation factors (BCF & BAF) and 
avoiding use of fish bio-concentration 
tests 
Ring trial to be conducted in 2014 
under the auspices of the OECD 
United States and 
European Commission 
SPSF for a TG on in vitro Fish Hepatic 
Metabolism approved in April 2014  
Endocrine Disruptor Test Methods 
Stably transfected human estrogen 
receptor- transcriptional 
activation assay for detection of 
estrogenic agonist-activity of 
chemicals  
Completed  OECD TG 455 (2009), updated 
2012 
Stably transfected human estrogen 
receptor- transcriptional activation 
assay for detection of estrogenic 
antagonist-activity of chemicals 
 
International validation study in 
progress 
 
JaCVAM and VMG NA 
liaisons 
To be added to TG 455 when validated 
and peer reviewed  
LUMI-CELL® human estrogen Completed  OECD TG 457 (2012) 
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Method Current Status Lead Action 
Organization 
International Acceptance 
receptor transcriptional activation 
assay: agonist and antagonist 
protocols 
CertiChem MCF-7 cell proliferation assay 
for the detection of human estrogen 
receptor agonists and antagonists 
International validation study 
completed. Protocol must be revised 
for adequate reproducibility 
NICEATM-ICCVAM; 
EURL ECVAM, JaCVAM 
and KoCVAM VMT 
liaisons 
 
Stably transfected CHO Androgen 
receptor-α transcriptional activation 
assay for detection of androgenic 
agonist and antagonist activity of 
chemicals. 
METI-sponsored validation is on-going JaCVAM and VMG NA 
liaisons 
 
MELN® human estrogen receptor 
transcriptional activation assay: agonist 
and antagonist protocols 
Validation study ongoing (EURL 
ECVAM). Peer review foreseen in 
2014. 
EURL ECVAM (lead), 
NICEATM-ICCVAM, 
JaCVAM 
To be added to the PBTG when 
validated and peer reviewed 
Stably Transfected Transactivation in 
vitro Assay to detect Androgen Receptor 
Agonists and Antagonists 
Validation study starts in 2014 EURL ECVAM (lead), 
NICEATM-ICCVAM, 
JaCVAM 
SPSF to develop a PBTG on ARTA 
approved in April 2013 
Genetic Toxicity Test Methods 
In vitro micronucleus test Completed  OECD TG 487 (2010) adopted in 
2014 
 
In vitro chromosome aberration 
assay 
Completed  OECD TG 473 (1997) adopted in 
2014 
In vivo/in vitro comet assay The peer review of the in vivo Comet JaCVAM (lead); EURL Adoption of draft OECD TG on the in 
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Method Current Status Lead Action 
Organization 
International Acceptance 
assay by the OECD Comet assay 
expert group has been finalised. 
Validation of in vitro study ongoing 
ECVAM, NICEATM-
ICCVAM, KoCVAM and 
Health Canada VMT 
liaisons 
vivo Comet assay expected in 2014 
Genotoxicity assays (micronucleus and 
comet) in 3D skin models 
Validation study ongoing Cosmetics Europe  (lead); 
EURL ECVAM support 
 
Transgenic rodent in vivo gene mutation 
assays. OECD TG 488 (2011) 
Draft TG to be updated. Health Canada  SPSF approved in April 2013. 
Carcinogenicity Test Methods 
Bhas cell transformation assay (CTA) Peer review coordinated by EURL 
ECVAM completed  
EURL ECVAM Recommendation 
published in 2013 
JaCVAM (lead); EURL 
ECVAM, NICEATM-
ICCVAM, and Health 
Canada VMT liaisons 
SPSF approved in 2010. New draft TG 
underwent one commenting round. 
Draft TG will undergo a second 
commenting round in view to be 
considered for adoption in April 2015 
 
SHE pH 6.7, SHE pH 7 and Balb/c 3T3 
cell transformation assays (CTAs) 
Pre-validation study and ESAC peer 
review completed Feb 2011; EURL 
ECVAM recommendation published. 
 
EURL ECVAM Draft TG was not adopted by WNT 26 
in 2014 but to be considered for 
adoption as Guidance Document after 
revisions 
Reproductive Test Methods 
Hand-1 Luc assay 
 
METI-sponsored validation is on-going JaCVAM (lead); EURL 
ECVAM, NICEATM-
ICCVAM, and Health 
Canada VMT liaisons 
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